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ABSTRACT 
 
 
 
Current hypotheses suggest that tumor originates from cells that carry out a 
process of “malignant reprogramming” driven by genetic and epigenetic 
alterations. Multiples studies reported the existence of stem-cell-like cells that 
acquire the ability to self-renew and are able to generate the bulk of more 
differentiated cells that form the tumor. This population of cancer cells, called 
cancer stem cells (CSC), is responsible for sustaining the tumor growth and is able 
to disseminate and migrate giving metastases to distant organs. Furthermore, CSCs 
have shown to be more resistant to anti-tumor treatments than the differentiated 
cells, suggesting that surviving CSCs could be responsible for tumor relapse after 
therapy. Nevertheless, the cancer stem-like properties are not well characterized 
yet. MicroRNAs (miRs) are small, noncoding RNAs (20-25 nucleotidies) that play 
a crucial role in biological processes including development, proliferation, and 
apoptosis. Previous investigations have linked miRs to the control of self-renewal 
and differentiation of normal stem cells. The aim of this study was to test the 
functional role of miRs in human Breast Cancer Stem Cells (BCSCs) also named 
mammospheres. We analyzed, by miR-Array, the miRs differentially expressed in 
BCSCs and their differentiated counterpart. Among several miRs, we focused our 
attention on miR-221 that was found increased in mammospheres. In order to 
validate data achieved in primary cultures, we obtained mammospheres from 
T47D, an immortalized breast cancer cell line. Interestingly, like primary cultures 
mammospheres, also T47D mammospheres exhibited increased levels of miR-221 
compared to T47D differentiated cells. Moreover, the overexpression of miR-221 
by a miR mimic in T47D differentiated cells was able to increase the number of 
mammospheres and the expression of stem cell protein markers. Among miR-221 
targets, we demonstrated, by luciferase-assay, that miR-221 targets the 3' 
untranslated region of DNMT3b, a DNA Methyl Transferase. Furthermore, our 
data showed that DNMT3b was able to repress the expression of some stemness 
genes, such as Nanog and Oct3/4, and mammospheres formation partially 
reverting miR-221 mediated effects on stemness properties. In conclusion, we 
hypothesize that miR-221 may contribute to breast cancer tumorigenicity 
regulating the stemness properties through DNMT3b expression. 
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1. BACKGROUNG 
 
 
 
1.1 The cancer stem cell theory 
 
 
 
1.1.1 Two models to describe cancer cells heterogeneity  
 
 
 
Cancer is a group of diseases characterized by uncontrolled cell proliferation. 
Tumor cells are able to invade nearby parts of the body and/or metastasize to more 
distant tissue. It is well established that tumors are heterogeneous entities and that 
not all cells are identical within a single tumor. In fact, cancer cells exhibit 
different phenotype and proliferation potential, express several differentiated 
markers and only a subfraction of tumor cells is able to self-renew in vivo 
xenograft models. 
Two theories have been proposed to explain the tumor growth and heterogeneity 
(Figure 1.1a). The “stochastic” theory suggests that all tumor cells are equipotent 
and that cancers arise from genetic and epigenetic mutations that affect the 
survival and reproduction of cells, providing a selective advantage and generating 
clonal heterogeneity. Differently, the “Cancer Stem Cell” theory holds that tumors 
are hierarchically organized like a normal tissue, with a subset of cells that possess 
an unlimited self-renewal potential (the ability to generate identical 
undifferentiated daughters) and give rise, through an altered differentiation 
process, to the “phenotypically different mature cells” (Weissman et al 2000). 
Owing to the analogy to tissue-specific stem cells, which are responsible for the 
maintenance and homeostasis of the adult tissue, these cells have been referred to 
as Cancer stem cells (CSCs) and have been proposed to be responsible for the 
maintenance and tumour progression. In contrast to the “stochastic” model of 
oncogenesis, where transformation results from random mutations and subsequent 
clonal selections, according to the CSC model, cancers would originate from the 
malignant transformation of a stem or progenitor cells through the deregulation of 
the normally tightly regulated self-renewal program or from transformation of 
committed cells that gain a self-renewal potential through dedifferentiation (Reya 
et al. 2001).  
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Figure 1. Two general models to explain the heterogeneity in solid cancers: A) The stochastic 
model; B) The cancer stem cells model.  
 
 
 
1.1.2 Relation between normal and cancer stem cells 
 
 
 
The CSC model assumes the tumours can be viewed as an “aberrant organ”. On 
the basis of this consideration, the principles of normal stem cell biology can be 
applied to cancer stem cells to better understand how tumours develop. Therefore, 
it is important to define the unique properties of normal stem cells. 
A normal adult stem cell is defined as an undifferentiated cell able to undergo 
unlimited cell division. It has the potential to give rise to both stem cells and 
daughter cells that differentiate into specialized cells, producing all cell types 
founded in mature tissue. A normal stem cell must possess two qualities to 
perform its natural function: self-renewal and differentiation. Self-renewal is a 
special cell property that enables a stem cell to produce another stem cell with 
essentially the same unspecialized phenotype and replication potential. 
Differentiation is the second function of a stem cell and involves the production of 
daughter cells that become tissue-specific specialized cells. The balance between 
self-renewal and differentiated cells maintains the tissue homeostasis by replacing 
senescent or damaged cells and ensures its correct function. It depends on systemic 
or local signals that are able to influence the cell division of stem cells (Morrison 
et al 2008). A stem cell can go through a symmetric division to generate two cells 
identical to itself. The ability to self-renew enables the expansion of the stem cell 
compartment and maintains a pool of undifferentiated stem cells. The stem cell 
might go through an asymmetric cell division to generate one cell that is identical 
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to itself and one cell that is distinct. The distinct cell goes through a series of cell 
divisions and differentiative steps to generate the ultimate terminally specialized 
cells. The cells that form the intermediates between stem cells and terminally 
differentiated cells are usually referred to as progenitor cells or transit amplifying 
cells. Differently to the stem cells, the progenitors are characterized by a reduction 
of self-renewal capacity and high rate of cell division. Therefore, in a tissue, cells 
are organised in a hierarchy, where only the stem cells present a long term self 
renewal and differentiation potential, whereas the more committed progenitors 
have a restrictive renewal potential (Morrison et al 1994, Morrison et al 1997). 
In a similar way to the normal tissue, the CSCs are at the apex of hierarchy and 
though an alteration of signalling that regulate normal stem features are able to 
expand the number of cancer stem cells and form a tumour mass composed by 
“differentiated cells” (Morrison et al 1994). 
 
 
 
 
Figure 2. Comparison of self-renewal during haematopoietic stem cell development and 
leukaemic transformation. Unlike normal haematopoiesis, where signalling pathways that 
regulate self-renewal are tightly regulated (top), during transformation of stem cells, the same 
mechanisms may be dysregulated to allow uncontrolled self-renewal. 
 
 
 
Normal stem cells (NSCs) and CSCs share a number of important phenotypic 
properties (Sell et al. 1994, Dontu et al. 2003). Particularly, they both have the 
capacity of unlimited self-renewal and extensive proliferation. In the case of 
normal stem cells, this is a tightly controlled process that occurs during the 
maintenance and repair of adult tissues and responds to environmental changes. In 
contrast, for the cancer stem cells this takes the form of self-sufficiency in growth 
signalling and uncontrolled cellular proliferation. NSCs and CSCs also share the 
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ability to be undifferentiated cells and to differentiate, giving rise to their 
progenies in tissue and to tumor heterogeneity, respectively. Moreover, both cell 
types exhibit a resistance to environmental toxins, chemotherapeutic and radiation 
agents, often as a result of multidrug resistance (MDR) via expression of ABC 
(ATP-Binding Cassette) family of transporter proteins. NSCs and CSCs also share 
the characteristic of being able to survive in anchorage independent conditions 
(resistance to anoikis), leading to migration for stem cells and potentially to 
metastatic disease for tumor. Finally, both cell types are long-lived with active 
telomerase activity and anti-apoptotic pathways.  
 
 
 
 
 
 
Figure 3. Similarities between NSCs and CSCs and their impact on stem-cell functionality 
and carcinogenesis. 
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1.1.3 Implication of the CSC theory in cancer treatment 
 
 
 
The CSC theory has important implications in cancer treatment. Current anti 
cancer therapy is effective for debulking the tumor mass but often treatment 
effects are transient, with occurring tumor relapse and metastatic disease. A 
possible explanation for the failure of anti-cancer therapies is that they fail to kill 
CSCs. As mentioned before, NSCs from various tissues tend to be more resistant 
to chemotherapeutics than mature cell types from the same tissues (Harrison and 
Lerner 1991). One of the reasons that could explain this is that NSCs express high 
levels of anti-apoptotic proteins (Feuerhake et al. 2000) and ABC transporter 
proteins (Zhou et al., 2001). CSCs also seem to overexpress transporter proteins 
and this could explain why these cells are more resistant to chemotherapeutics than 
committed/differentiated tumor cells with limited proliferative potential. Even 
therapies that cause complete regression of tumors might spare enough CSCs to 
allow regrowth of the tumors. Targeting differentiated as well as tumor stem cells 
is a prerequisite for therapy to be efficient. On the other hand, it is noteworthy to 
consider the recent emerging possibility of the existence of equilibrium between 
CSCs and non-CSCs within tumors. In particular, whereas CSCs can differentiate 
into non-CSCs giving rise to the tumor heterogeneity, the reverse process would 
be possible: non-CSCs, could be reprogrammed into CSCs. This phenotypic 
plasticity has implications for cancer treatment: if non-CSCs can give rise to 
CSCs, therapeutic elimination of CSCs may be followed by their regeneration 
from residual non-CSCs, allowing tumor regrowth and clinical relapse. 
 
 
 
 
 
 
Figure 4. Comparison between conventional therapies and CSCs targeted therapies 
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1.1.4 Evidence for CSCs 
 
 
 
CSCs were first discovered in Acute Myeloid Leukemia (AML). In this case, 
thanks to the markers CD34+CD38- that are normally expressed on the surface of 
normal myeloid stem cells, Lapidot and colleagues were able to distinguish AML 
stem cells from the remaining AML cells with limited proliferative potential 
(Lapidot et al. 1994; Bonnet and Dick 1997). This cell population (approximately 
0,2%) was found to be the only capable to propagate leukaemia in 
immunodeficient mice, providing evidence that not all AML cells are tumorigenic 
in vivo and that only the small subset of CSCs was capable of regenerating the 
cancer. The first solid CSCs were identified in breast tumors (Al-Hajj et al. 2003), 
and then CSCs were isolated from brain (Singh et al. 2003), colon (O’Brien et al. 
2007), melanoma (Fang et al. 2005), pancreatic (Hermann et al. 2007), prostate 
(Collins et al. 2005), ovarian (Bapat et al. 2005), lung (Ho et al. 2007) and gastric 
(Fukuda et al. 2009) cancers. 
Breast cancer was the first tumor in which a subpopulation with cancer stem 
characteristics has been isolated by Clarke and colleagues. In this study, in nine 
breast cancer samples, a minority of cells, expressing the surface marker 
phenotype CD44+CD24-, were able of generating tumors in NOD/SCID mice even 
when implanted in low numbers. By contrast, the other cancer cell populations, 
such as CD44+CD24+, failed to generate tumors even when implanted in high 
numbers (Al-Hajj et al. 2003).  
Using a clonogenic sphere culture technique, CSCs were isolated from human 
brain tumors (glioblastomas) as spherical structure called neurospheres (Singh et 
al. 2003). These neurospoheres are highly enriched for cell surface marker CD133 
and nestin (a neural stem cell marker), have a marked proliferation capacity, self- 
renewal and are able of in vitro differentiation into phenotypes identical to the 
tumor in situ. The original culture methodology employed by Singh has been used 
to isolate and characterize cells suspected of being stem or progenitor cells also in 
other cancer types. 
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1.1.5 Origin of CSCs 
 
 
 
Initially the CSC theory considered the normal stem cells as the appropriate 
candidates for tumor initiating thanks to their longevity and possibility to 
accumulate mutation by the time. But recently there has been some controversy 
about the nature of the cells that serve as targets of transformation. A revisiting of 
the theory proposes that the cells of origin, the normal cell that acquires the first 
cancer promoting-mutation, is not necessary related to the CSCs, the cellular 
subset that uniquely sustain malignant growth. In fact, in a variety of 
malignancies, evidence for the clonal generation of tumors that display markers of 
multiple lineages has confirmed the stem cell as the cell of origin. However, in 
other cases, such as acute promyelocitic leukemia and chronic myelogenous 
leukemia, there is evidence for the transformation of progenitor cells. The 
transformation of progenitor cells might require mutations that allow them to 
undergo self-renewal, normally a process limited to stem cells.  
Since specific pathways are involved in the embryonic and/or tissue stem cells 
self-renewal, it is not surprising that their altered maintenance in NSCs or their 
activation in non-stem cells, provide for a subpopulation with features indicative 
of stem cells. In several types of cancer, poorly differentiated tumors show 
expression of genes normally found in embryonic stem cells, including Nanog, 
Oct-4, Sox-2 and c-Myc (Ben-Porath et al. 2008).  
Recently, it has been proposed that progenitors or differentiated cells gain features 
of stem cell through the induction of the epithelial-mesenchymal transition (EMT), 
a process that triggers the transition of epithelial cells to a less differentiated 
(mesenchimal-like) stage. Studies have shown that EMT induction creates 
populations of cells that are highly enriched for CSCs properties in transformed 
mammary epithelial cells (Mani et al. 2008; Morel et al. 2008) and that CSCs stem 
isolated from mammary epithelial cells cultures express markers similar to those 
of HMLEs that have undergone an EMT.  
Poor tumor differentiation due to extensive EMT may therefore predispose cells to 
becoming CSCs.  
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Figure 5. Three are the hypotheses of how a cancer stem cell may arise: (1) A stem cell 
undergoes a mutation (2) A progenitor cell undergoes two or more mutations or (3) A fully 
differentiated cell undergoes several mutations that drive it back to a stem-like state. In all three 
scenarios, the resultant cancer stem cell has lost the ability to regulate its own cell division. 
 
 
 
1.2. The human mammary gland and stem cells in normal human breast 
 
 
 
In humans, the mammary gland is a hormone sensitive, branching, and bilayered 
epithelial organ and is embedded within a fibrous and fatty connective tissue 
called stroma. The functional units of the mammary gland are comprised of 
terminal ducts and alveoli (lobules), which together form the terminal duct lobular 
units (TDLUs) and are responsible for the milk production during pregnancy. 
TDLUs form the branches of a greater ductal-lobular system composed of an inner 
layer of polarized luminal cells and an outer layer of myoepithelial cells. 
Myoepithelial cells are contractile cells that form a sheath around the ductal 
network of the breast and are characterized by expression of common Acute 
Lymphoblastic Leukaemia Antigen (CALLA) (Gusterson et al., 1986), Thymocyte 
Differentiation Antigen (Thy-1) (Gudjonsson et al., 2002), Alpha-Smooth Muscle 
actin (α-SMA) (Gugliotta et al., 1988), Vimentin (Guelstein et al., 1988), and 
Cytokeratin (CK) 5 and CK14 (Taylor-Papadimitriou et al., 1989). Luminal 
epithelial cells are cuboidal/columnar cells that line the ducts and alveoli. They are 
characterized by expression of Mucin-1 (MUC-1) (Petersen et al. 1986), epithelial 
cell adhesion molecule (EpCAM) (Latza et al. 1990), and CK7, CK8, CK18, and 
CK19 as well as estrogen receptor (ER) and progesterone receptor (PR).  
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The human breast is a dynamic gland and, unlike other organs that develop during 
embryogenesis and preserve their architecture throughout adult life, its 
morphology changes during embryonic development, pubertal, 
pregnancy/lactation, within menstrual cycles, and involution during menopause. 
These changes are under control of estrogen and progesterone hormones. During 
pregnancy and lactation, the breast goes through further rounds of development 
with an increase in cell growth and differentiation of the luminal epithelial lineage 
into functional milk-secreting alveolar cells. Cessation of lactation following 
weaning is accompanied by massive apoptosis and tissue remodeling, and the 
gland reverts to a structure resembling that before pregnancy. 
 
 
 
 
 
 
 
Figure 6. Schematic representation of the human breast structure. 
 
 
 
Development and remodeling of mammary epithelium is hypothesized to be via 
the mammary stem cells, which are defined as those cells with high proliferative 
potential and differentiation ability in order to generate both the ductal and 
alveolar structures of the mammary gland.  
The first who demonstrated, in the late 1950s, the existence of adult stem cells in 
mammary was DeOme and colleagues. Using a vivo serial transplantation assays, 
DeOme demonstrated that a small tissue fragment, transplanted into pre-cleared fat 
pads, could generate a mature functional mammary tree containing ductal, alveolar 
and myopethelial cells (Daniel et al. 1968). More recently, Dontu and colleagues 
developed a culture system to isolate and propagate in vitro human breast 
stem/progenitor cells in an undifferentiated state as non-adherent spherical 
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clusters, termed ‘mammospheres’. Mammospheres have been demonstrated to be 
clonally derived from single self-renewing cells. Moreover, they encompass 
undifferentiated precursors capable of differentiating along the three cell lineages 
of the mature mammary gland epithelium (luminal, myoepithelial and alveolar 
cells) in reconstituted three-dimensional culture systems (Dontu et al. 2003). 
The isolation and characterization of mammary stem cells is fundamental to 
understanding mammary gland development and tissue homeostasis as well as 
breast oncogenesis. The most useful markers for isolating human mammary stem 
cells are the epithelial cell adhesion molecule EpCAM, the CD49f and, to a lesser 
degree, the luminal cell-specific glycoprotein MUC1, the common acute 
lymphoblastic leukemia antigen CALLA and the GPI-linked glycoprotein Thy-1 
(Stingl et al., 1998; Stingl et al., 2001; Eirew et al., 2008; Villadsen et al., 2007; 
Raouf et al., 2008). EpCAM is an epithelial-specific molecule that is expressed at 
high level by luminal cells; CD49f is an integrin known to participate in cell 
adhesion as well as cell surface mediating signaling and displays a pattern of 
expression inverse to that of EpCAM (Stingl et al. 1998; Carter et al. 1990). 
Although both EpCAM and CD49f are not particularly useful for identifying 
different subsets of HMECs when separately used, when combined they permit a 
number of distinct cell types to be resolved by flow cytometry. MUC1 is a cell 
surface glycoprotein expressed by most epithelial cells and involved in cell-cell 
and cell-substrate adhesion. CALLA is a membrane-associated endopeptidase 
overexpressed in many neoplastic cell types and Thy1 is a membrane-associated 
glycoprotein involved in cell adhesion, migration and proliferation. In vitro 
analyses of human mammary epithelial colony-forming cells (Ma-CFCs) have 
demonstrated the existence of three distinct progenitors within the human 
mammary epithelium. 1) The luminal-restricted progenitors which generate 
colonies that are composed of cells with a luminal cell phenotype (expressing 
CK8, 18, 19 and 9). Replating of these colonies in secondary CFC assays reveals 
that cells of these colonies are indeed restricted to a luminal cell fate, since they 
only form pure luminal cell colonies. These luminal restricted progenitors display 
the phenotype EpCAM high CD49f+ MUC1+ CALLA- Thy1- (Stingl et al. 2001; 
Villadsen et al. 2007). 2) The bipotent progenitors display EpCAM low CD49f 
high MUC1- CALLA+ Thy1+ antigenic phenotype. These progenitors generate 
colonies that are characterized by a central core of CK14−CK18+CK19+MUC1+ 
luminal cells and peripheral zone of CK14+ basal cells. Single-cell cloning of these 
progenitors confirms that these mixed colonies are clonal in origin (Stingl et al. 
2001) 3) The myoepithelial restricted progenitors generate colonies that are 
composed solely of CK14+CK18−CK19−MUC1− basal-like cells. Although recent 
findings have clarifying some aspects of mammary hierarchy, the precise number 
and nature of the intermediates remain still elusive. A simple model that 
accommodates much of the mounting data was proposed by Visvader and 
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colleagues and show that the stem cell gives rise to a common progenitor that 
produces committed progenitor cells for either the myoepithelial or luminal 
epithelial lineages (ductal and alveolar sublineages). Furthermore, the luminal 
progenitor subpopulation can commit to either a ductal or alveolar cell fate, 
dependent on the developmental stage (puberty or pregnancy) (Visvader et al. 
2009). 
 
 
 
 
 
Figure 7. Model of the differentiation hierarchy within mammary epithelium. A stem cells 
give rise to a common progenitor, also referred as a bipotent progenitor cell. The common 
progenitor produces committed progenitor cells for either the myoepithelial or luminal epithelial 
lineages. During pregnancy, the alveolar progenitor may exhibit bipotential capacity.  
 
 
 
1.3 Breast cancer 
 
 
 
Breast cancer is a heterogeneous group of tumors originating from the epithelial 
mammary tissue. It is one of the most common causes of cancer-related mortality 
in women worldwide with more than one million women diagnosed every year and 
half a million dying for this disease. Worldwide, breast cancer accounts for 22.9% 
of all cancers (excluding non-melanoma skin cancers). Thanks to the widespread 
use of screening mammograms, the majority of breast cancers is diagnosed before 
clear symptomatology appears (Akhigbe et al. 2010). In other cases, the most 
common symptoms are the identification of a new lump or mass, a change in the 
aspect of the skin (redness, swelling), the presence of a secretion (in particularly if 
blood) or the retraction of the nipple. Sometimes a breast cancer can spread to 
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lymph nodes under the arm or around the collarbone and cause a lump or swelling 
there, even before the original tumor in the breast tissue is large enough to be felt. 
Multiple factors, known and unknown, contribute to human breast cancer. 
Environment, hereditary, hormonal, and reproductive factors are the most 
important associated risk factors associated with breast cancer (Anderson et al. 
2014). The majority of breast cancer cases are not hereditary and over 70% of 
breast cancers have been attributed to environmental agents (chemical carcinogens 
exposition, tobacco smoke, alcohol, and diet).  However, about 5% to 10% of 
breast cancer cases are thought to be hereditary and the most common cause of 
hereditary breast cancer is an inherited mutation in the BRCA1 and BRCA2 genes 
(Teng et al. 2008). Estrogen hormone exposition and reproductive factors also play 
a crucial role in breast cancer onset. After an early embryonic/fetal growth of 
breast, the major development processes takes place during puberty and 
pregnancy. From puberty and onward, systemic steroid hormones inflict changes 
in the epithelium as well as the adjacent stroma through each estrous cycle, and at 
menopause when hormonal levels change, the gland involutes. Developmental 
changes associated with cycling and pregnancy are critical parameters of cancer 
susceptibility and for this reason the risk factors for the breast cancer include early 
menarche, late menopause and late first pregnancy.  
 
 
 
1.3.1 Breast cancer: a heterogeneous disease 
 
 
 
Breast cancer, rather than constituting a unique entity, comprises heterogeneous 
tumors with different clinical characteristics, biologic behavior, and responses to 
specific treatments (Bertos et al. 2011). Over the years, many breast cancer 
classification systems have been developed and have tried to be used as toll for 
prognosis and treatments dosing. The different breast cancer classification systems 
are based on several tumor-intrinsic features that categorized breast tumors into 
multiple subtypes, including histological, immunopathological and molecular 
subtypes. 
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1.3.2 Histopathology and immunological classification 
 
 
 
Classical pathology has segregated breast tumors into multiple categories, based 
on their overall morphology and structural organization. Breast cancers can be 
categorized into in situ carcinoma and invasive or infiltrating carcinoma (Figure 
1.4 A) In situ breast carcinoma is further sub-classified as ductal or lobular, if they 
originate from ducts or lobules respectively. In Situ Ductal Carcinoma (DCIS) is 
considerably more common than in situ Lobular Carcinoma (LCIS) and includes a 
heterogeneous group of tumors. Particularly, DCIS has traditionally been further 
sub-classified on the basis of the architectural features of the tumor which has 
given rise to five well recognized subtypes: Comedo, Cribiform, Micropapillary, 
Papillary and Solid (Gautam et al. 2010; Figure 1.4a). Similar to in situ 
carcinomas, invasive carcinomas are a heterogeneous group of tumors 
differentiated into histological subtypes. The major invasive tumor types include 
infiltrating ductal carcinoma (IDC) (Figure 1.4 B), invasive lobular (Figure 1.4 C), 
ductal/lobular, mucinous (colloid), tubular, medullary and papillary carcinomas. 
Among these tumor types, IDC is the most common subtype accounting for 70–
80% of all invasive lesions (Li et al. 2005). IDC is further sub-classified as either 
well-differentiated (grade 1), moderately differentiated (grade 2) or poorly 
differentiated (grade 3) based on the levels of nuclear pleomorphism, 
glandular/tubule formation and mitotic index (Figure 1.4 A). Although this 
classification has been a valuable tool for several decades and has been useful as 
prognostic value, the outcome and the variable clinical response of patients to 
therapy reveals that a considerable heterogeneity linking to therapy still exists. For 
this motif, it has become necessary to more accurately stratify patients based on 
relative risk of recurrence or progression. These demands have led to the 
generation of several newer classification systems that uses the presence of 
specific markers to both define subtypes with differential prognosis and provide 
tumors responds to treatments. The main markers assessed are estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal receptor 2 (HER2). 
Combinations of these markers allow for the assignment of individual cases to 
specific categories, namely ER+ (ER+/HER2–), HER2+ (ER–/HER2+), triple 
negative (TN; ER–/PR–/HER2–), and triple positive (ER+/PR+/HER2+). 
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Figure 8. Hystological subtypes of breast cancer. (A) Hystological classification of breast 
cancer. (B, C) Schematic representation of invasive Ductal Carcinoma (B) and Invasive Lobular 
Carcinoma (C). 
 
 
 
1.3.3 Molecular breast cancer classification 
 
 
 
Over the past decade, the advent of high-throughput microarray-gene expression 
profiling has facilitated relatively large-scale studies leading to the identification 
of multiple molecular subtypes. These molecular subtypes has been described and 
defined by distinct transcriptional signatures that partially recapitulate the original 
immunopathological classes, and adding an additional level of detail (Sorlie et al. 
2003; Perou et al. 2000; Sorlie et al. 2001). Two luminal subtypes (A and B) 
contain principally ER+ cases and are distinguished by the presence of genes 
regulated by the ER signaling pathway. The luminal A subtype is associated with 
higher levels of ER and ER-regulated genes, low proliferation, and improved 
overall outcome (Sorlie et al. 2001; Perou et al. 1999; Perreard et al. 2006). 
** 22*
Luminal B tumors are ER+ and/or PR+ and appear to have an increased 
proliferation and relatively worse prognosis. The molecular ERBB2+ subtype 
generally (but imperfectly) overlaps with IHC-defined HER2+ tumors (Perou et 
al., 2000), and previously was associated with poor outcome, now exhibit an 
improved overall outcome when treated with therapies anti-ERBB2. The basal or 
basal-like subtype broadly corresponds to the TN (ER–/PR–/HER2–) cohort and is 
linked to the worst prognosis (Nielsen et al. 2004). A normal-like molecular 
subtype resembles normal epithelial tissue and may comprise cases in which 
samples contain large amounts of non-tumor tissue (Parvin et al. 2012; Huang et 
al. 2012; Parker et al. 2009) 
. 
 
 
 
 
 
Figure 9. Molecular classification of breast cancers. 
 
 
 
1.4 Breast cancer stem cells 
 
 
 
Al Hajj and colleagues were the first that identify a subpopulation of human breast 
cancer stem cells, which is able to initiated tumors in immune-deficient 
NOD/SCID mice (Al Hajj et al., 2003). They used a set of cell surface markers to 
sort cells with an increased tumorigenic capacity. In particular, cells which were 
CD44+ CD24 low EpCAM+ and lineage- (it refers to non-CD45 and CD31 
expressing cell to rule out blood or endothelial cell contamination) isolated from 
one primary breast cancer and eight metastases, were able to form heterogeneous 
tumors eight out of nine times. As few as 200 CD44+ CD24 low EpCAM+ lin- cells 
transplanted into NOD/SCID mice could form tumors with 100% efficiency, while 
CD44- CD24+ EpCAM- cells formed no tumors. CD24, also known as heat stable 
antigen (HAS), is an adhesion molecule specifically expressed in luminal 
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epithelial cells in human mammary gland. The tumors generating by this subset of 
cells contained not only the CD44+ CD24 low EpCAM+ lin- population but also the 
phenotypically diverse non-tumorigenic cells that comprise the bulk of tumors. 
Subsequently, Ponti and colleagues carried out a study on sixteen breast lesions 
(thirteen primary invasive carcinomas, one recurrent carcinoma and two 
fibroadenomas) and using the sphere culture technique, were able to obtain three 
long-term primary cultures, which had self-renewing capacity and could 
differentiate into the different breast lineages (Ponti et al. 2005).  
 
 
 
1.4.1 Pathways involved in breast cancer self renewal 
 
 
 
The understanding of the pathways that govern the self- renewal of normal stem 
cells, and the ways in which these are deregulated during carcinogenesis, results 
fundamental for understanding the cancer stem cells biology. The pathways of 
Hedgehog, Notch, Wnt, RTKs and a transcription factor Bmi-1 have been found to 
play an important roles in mammary gland development and to be involved in the 
regulation of stem cell self-renewal and differentiation. Recent evidence has 
shown that the deregulation of these pathways has a pivotal role in mammary 
carcinogenesis. 
 
The Hedgehog signaling. The Hedgehog ligands (Shh, Dhh, and Ihh) are secreted 
glycoproteins. After secretion, these ligands bind to the hedgehog-interacting 
protein 1 (Hip1) and Patched (Ptch), which are transmembrane receptors for these 
ligands (Ingham et al. 1991). Two transmembrane proteins, Ptch and Smoothened 
(Smo), form the receptor complex in the absence of ligands. Ptch binds to Smo and 
blocks its function (Taipale et al. 2002). This inhibition is relieved in the presence 
of ligands, and Smo interacts in a signalling cascade that results in activation of 
the transcription factors Gli1, Gli2, and Gli3 (Sasaki et al. 1999). Gli proteins in 
turn translocate into the nucleus and control target gene transcription. Gli regulates 
the transcription of several genes, including those controlling cell proliferation 
such as cyclin D, cyclin E, Myc, components of the epidermal growth factor 
pathway, and angiogenesis components including PDGF (platelet derived-growth 
factor) and VEGF (vascular endothelial growth factor) (Lewis et al. 2004). GLI 
family also directly regulate Nanog gene, a critical mediator of self-renewal (Po et 
al. 2010). Using the mammosphere-based culture system to examine the role of 
hedgehog signalling in mammary cell fate determination, Dontu showed that the 
addition of recombinant Shh can stimulate the formation of primary and secondary 
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mammospheres suggesting that hedgehog signalling is involved in mammary stem 
cell self-renewal (Liu et al. 2006). The importance of hedgehog signalling in 
carcinogenesis has been demonstrated by the fact that many of the genes involving 
hedgehog signalling are known oncogenes, including Smo, Shh, Gli-1, and Gli-2, 
or that Ptch1 can function as a tumor suppressor (Lewis et al. 2004) 
 
Notch signalling. Activation of the Notch pathway depends on binding of a Delta-
type or Jagged-type ligands expressed on the cell surface to a Notch-like receptor 
on the surface of a neighboring cell (Bettenhaussen et al. 2005, Rebay et al. 1991). 
The interaction between ligand and receptor causes cleavage of NOTCH, releasing 
the soluble intracellular domain (Schroeter et al. 1999). This intracellular NOTCH 
fragment translocates to the nucleus, where it associates with CBF1/Su(H)/LAG1 
(CSL) family proteins (Jarriault et al. 1995). Notch binding switches the activity of 
CSL DNA binding proteins from transcription repressors to transcription 
activators to mediate the expression of target genes (Jarriault et al 1995).  
Notch signaling plays an important role in regulation of embryonic development 
(Poulson et al. 2012, Swiatek et al. 1994), by regulating both restriction and 
specification of cell fate (Parks et al. 1997, Kim et al. 1996). 
Dontu and colleagues found that Notch signalling acts as a regulator of 
asymmetric cell fate decisions during development and that Notch activation 
promoted the self-renewal of stem cells, whereas in later stages of development it 
biased cell fate decisions in mammary progenitor cells toward the adoption of a 
myoepithelial cell fate versus an epithelial cell fate (Dontu et al. 2004). 
In cancer, increased expression of Notch pathway components has been associated 
with EMT process, and enhanced migration and invasion of mammary cancer 
cells, whereas inhibition of Notch signaling reverted the EMT phenotype and 
decreased expression of vimentin, Snail, Slug, and ZEB1 in human breast cancer 
cell lines (Wang et al. 2009, Bao 2011). These proteins are positive marker and/or 
regulator of the EMT allowing a change in the phenotype toward and 
undifferentiated status. Besides induction of EMT, Notch overexpression mediated 
upregulation of CSC markers CD44 and ESA (Bao et al. 2011). In vitro, 
overexpression of the constitutively active form of Notch4 inhibits the 
differentiation of normal breast epithelial cells. Uyttendaele and colleagues 
demonstrated that Notch4 has also an important role in carcinogenesis 
(Uyttendaele et al. 1998). Transgenic mice harbouring a constitutively active 
Notch4 exhibited arrested mammary gland development, and eventually developed 
poorly differentiated adenocarcinomas.  
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Wnt signalling. The canonical WNT pathway describes binding of extracellular 
Wnt to Frizzled family cell surface receptors and LRP co-receptors, leading to 
activation of Dishevelled (Bhanot et al. 1996,Cong et al. 2004). Dishevelled 
inhibits activity of the axin/GSK-3/APC complex which mediates proteolytic 
degradation of β-catenin, resulting in an increase of β-catenin levels (Kishia et al. 
1999, Rubinfield et al. 1996). Interaction of β-catenin with LEF/TCF transcription 
factor family members promotes the expression of target genes (Behrens et al. 
1996,Molenaar et al. 1996). Wnt/β-catenin signaling is important for maintenance 
of the self-renewal capacity in embryonic stem cells and induces Oct-3/4 
dependent upregulation of the stem cell factor Nanog (Takao et al. 2007). 
Conversely, overexpression of Oct3/4 increased β-catenin activity and inhibited 
cell differentiation (Hochedlinger et al. 2005). Besides the canonical Wnt/β-
catenin pathway, there are at least two non-canonical pathways downstream of 
WNT. The WNT/calcium pathway signals via heterotrimeric G-protein dependent 
activation of the phosphatidylinositol pathway, which leads to release of 
intracellular Ca2+ (Slusarski et al. 1997). As a consequence, Ca2+ sensitive 
enzymes including PKC and Ca2+/calmodium-dependent kinase (CaMK)II are 
activated (Sheldahl et al. 1999, Küh et al. 2000). Wnt/calcium mediated 
upregulation of PKC leads to increased cell migration (Dissanayake et al. 2007). 
Moreover, acquisition of mesenchymal morphology, accompanied by upregulation 
of Snail and loss of E-cadherin, a key molecule at the tight junction that establish 
and maintain cell-cell adhesion and epithelial phonotype, indicates that increased 
expression of PKC also contributes to EMT. 
 
Bmi-1. Bmi-1 is a transcriptional repressor belonging to the polycomb (PCG) 
group of transcription factors and is essential in maintaining chromatin silencing 
(Valk-Lingbeek et al. 2004). Bmi1 was first identified as an oncogene in 
lymphoma where it collaborates with c-Myc to promote lymphomagenesis and 
regulated cell proliferation and senescence through inhibiting the INK4A (Jacobs 
et al. 1999, Jacobs et al. 1999). Bmi1 was shown to be required for maintaining of 
both normal and leukaemia stem cells (Lessar et al. 2003, Park et al. 2003). It was 
later shown to be involved in the self-renewal of neuronal, mammary epithelium, 
pancreatic (including β-cell). Several recent studies have suggested a link between 
Bmi-1 and mammary carcinogenesis and that it resulted to be overexpressed in 
several human breast cancer cell lines (Liu et al. 2006). Furthermore, it was found 
that Bmi-1 regulates telomerase expression in mammary epithelial cells, avoiding 
the senescent process (Dimri et al. 2002).  
 
RTK-Akt signalling. Receptor Tyrosine Kinases (RTKs) mediate signal 
transduction of multiple oncogenic cytokines or growth factors, including the 
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) that are 
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used in culturing cancer stem cells in vitro (Dontu et al., 2003). Among these RTK 
pathways, the EGFR-mediated growth signalling through phosphoinositide 3-
kinase (PI3K)/Akt is one of the most critical and best characterized pathways in 
malignant cancers. Frequently, these receptors are upregulated or mutated, leading 
to increase EGFR-Akt signalling in cancer cells (Moscatello et al., 1998; Choe et 
al., 2003). Isteed, Chan and colleague demonstrated that EGFR kinase inhibitor 
reduces epithelial proliferation in normal and premalignant breast cancer cells 
(Chan et al. 2002). In breast cancer, HER2, a member of EGFR family, plays an 
important role in breast development and mammary carcinogenesis (Palafox, 
2012). Although HER2 itself has no known ligand, it forms heterodimers with 
ligand-activated EGFR, HER3, and HER4. Several lines of evidence indicate that 
HER2 is an important regulator of the CSC population in HER2 breast cancers. 
Korkaya and colleagues showed that HER2 overexpression increases CSCs and 
HER2 blockade decreases the CSC population in breast cancer cell lines and 
mouse xenografts. In addiction, HER2 overexpression induces the expression of 
stem cell-related genes and activates the PI3-K/Akt pathway (Korkaya et al. 2008). 
 
Specific transcriptional factors and maintenance of breast cancer stem cells. 
Sox2, Oct3/4 and Nanog are core components of stem cell transcription factor 
network and play crucial roles in maintaining embryonic stem cells and somatic 
stem cells (Ellis et al., 2004; Loh et al., 2006; Tay et al., 2008; Fong et al., 2008). 
They are also critical factors for cell reprogram and the generation of inducible 
pluripotent stem cells (iPS) (Takahashi and Yamanaka 2006). These 
transcriptional factors are differentially expressed in breast cancer cell line and are 
important for BCSCs maintenance (Ben-Porath et al. 2008). Overexpression of 
Sox2, Oct3/4 or Nanog enhanced tumorigenicity of breast cancer cells and 
promoted the self-renewal expansion of CD24- CD44+ CSC subpopulation (Luet 
al. 2013, Leis et al. 2012, Kim et al. 2011). In contrast, knockdown of these genes 
significantly affected the growth of breast CSCs. 
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Figure 10. Pathways involved in breast cancer stem cells regulation. 
 
 
 
1.5 microRNAs 
 
In the last decade, many non coding-RNAs were found to regulate a wide variety 
of biological process. Among these, microRNAs (miRs) are the best characterized. 
miRs are a class of endogenous non coding-RNA with a length of 21-25 
nucleotide that play an important role in the negative regulation of gene expression 
blocking the translation or directly cleaving the target mRNA. The biogenesis of 
miRs is a complex and coordinate process in which are involved different enzyme 
and protein (Bartel et al. 2004).  
MiRs gene is first transcribed by RNA polymerase II into a long primary transcript 
(pri-miR) in the nucleus. Generally, pri-miRs show a 33 bp stem and a terminal 
loop structure with flanking segment. Primary miR processing starts in the nucleus 
where Drosha, a RNAseIII enzyme, removes the flanking segment and 11 bp of 
the stem region and convert the pri-miR into precursor miR (pre-miR). Pre-miRs 
are 60-70 nt long hairpin RNAs with 2-nt overhangs at 3’ end. Pre-miRs are 
transported into the cytoplasm for further processing to become mature miRs. The 
transport occurs through a nuclear pore complex and is mediated by the RanGTP-
dependent nuclear transport receptor exportin-5 (EXP5). EXP5 exports the pre-
miR out of the nucleus where hydrolysis of the GTP results in the realise of pre-
miR. In the cytoplasm the pre-miR is subsequentially processed by Dicer, an 
endonuclease cytoplasmatic RNAse II enzyme, to create a mature miR. Dicer is a 
highly specific enzyme that cleaves pre-miRs in 21-25 nt long miR duplex, of 
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which each strand bears 5’ monophoshate, 3’ hydroxyl group and 3’ 2-nt 
overhang. Of a miR duplex, only one strand, designed the miR strand, is selected 
as the guide of the effector RNA-induced silencing complex (RISK). The core 
component of RISK is a member of Argonaute (Ago) subfamily proteins. During 
RISK loading, the miR duplex are incorporated into Argo proteins. Risk loading is 
not a simple process but also an ATP dependent active process. After risk loading, 
the duplex is unwound and the complex maintains only the miRstrand (Bartel et al. 
2004, Lee et al. 2002, Gregory and Shiekhattar 2005). 
miRs target sites lie in the 3’untranslating region (UTR) because the movement of 
ribosome (the translation) counteracts RISK binding. Typically, a target mRNA 
bears multiple binding site of the same miR and/or several different miRs. Not all 
nucleotidies of a miR contribute equally to RISK target recognition. The 
recognition of the target is largely determined by base paring of nucleotides in the 
seed region and is enhanced by additional base-pairing in the middle of the 3’UTR 
region. The binding of RISK to 3’UTR of mRNA, through the action of AGO 
protein, is capable of RNA cleavage, but this reaction requires extensive base 
pairing between the miR strand and mRNA target. This is the same mechanism 
used by siRNA. 
 
 
 
 
 
Figure 11. Biogenesis of miRs 
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If the complementary between the miR strand and the mRNA is limited, RISK is 
incapable to cleave target. In such case, Ago protein can recruit other factors 
required for translation repression and subsequentially mRNA 
deadenylation/degradation (Lewis et al. 2003). To date, the exact mechanism used 
by RISK to repress translation is subjected of debate. Between the mechanisms 
proposed at least six seems to be possible: RISK could induce deadenylation of 
mRNA which decrease the efficiency of translation by blocking mRNA 
circularization, RISK could block the cap at 5’ or the recruitment of ribosomal 
subunit 60S; RISK could block the initial step of elongation or could induce 
proteolysis of nascent peptides; RISK could initial recruits mRNA to processing 
bodies, in which mRNA is degraded or temporary stored in an inactive form. 
These models do not necessarily exclude each other. 
 
 
 
 
Figure 12. Various mechanism of regulation of gene expression by RNA-induced silencing 
complex (RISK). 
 
 
 
1.5.1 Function of miRs in animals 
 
 
 
MiRs have key roles in the regulation of distinct process in mammals. MiRs play 
an evolutionally conserved role in the development and in physiological function 
in animal. Knockout gene strategies have been used in different mammals to study 
the role of miRs in development processes. A dicer knockout was made in 
Zebrafish and this revealed a role of the family of miR-140 in Zebrafish 
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neurogenesis. MiRs can also control late stage mouse development by miR-196 
which act upstream Hox B8 and Sonic hedgehog in limb formation. miR-182 is 
preferentially expressed in B-lymphocytes and regulates mouse hematopoietic 
lineage differentiation (Chen et al. 2004). miR-133 and miR-1 are essential for the 
differentiation of ESCs into cardiomyocytes. MiR-122a is highly express in adult 
livers and its expression is upregulated during mammalian liver development 
(Chang et al. 2004). In mouse ESCs several miRs have been shown to promote 
differentiation by targeting genes encoding transcription factors involved in the 
maintenance of stem cell identity. For instance, miR-200c, miR-203 and miR-183 
cooperate to repress Sox2 and Klf4 (Wellner et al. 2009). Upon retinoic-acid-
induced differentiation of mESC, miR-134, miR-296 and miR-470 are up-
regulated and target the coding regions of Nanog, Oct3/4, and Sox2 (Tay et al. 
2008). Recent studies have also reveal that miR can act as important molecular 
mediator of the stemness process in adult stem cells. For example, miR-125a 
controls HSC population size by inhibiting their apoptosis via translational 
repression of the pro-apoptotic protein Bak1 (Guo et al. 2010). miR-128 and miR-
181 are expressed only in early progenitor cells and prevent the differentiation of 
all hematopoietic lineages. Let-7b overexpression inhibits NSC proliferation and 
accelerates neural differentiation by targeting TLX and cyclinD1 involved in the 
regulation of cell cycle progression. 
Some miRs regulate diverse physiological process, for example miR-375 is 
express in pancreatic islet and inhibits glucose-induced insulin secretion. 
Several studies have establish a role of MiRs in also in other cellular processes 
including apoptosis, proliferation, stress response, metabolism etc. 
 
 
 
1.5.2 miRs in cancer 
 
 
 
Recent studies have demonstrated a link between deregulated expression of miRs 
and carcinogenesis. A number of miRs have been shown to function as oncogenes 
or tumour suppressor during tumor development. The first evidence for miR 
involved in human cancer came form a study by Calin (Calin et al. 2002). 
Examining a recurring deletion at chromosome 13q14 in the search of tumour 
suppressor gene involved in Chronic Lymhocitic Leukaemia (CLL), it was found 
that the region of deletion encodes two miRs, miR-15a and miR-16-1. Subsequent 
investigations have confirmed the involvement of these two miRs on the 
pathogenesis of CLL (Calin et al. 2005, Cimmino et al. 2005).  
To date, a lot of miRs have been characterized for their function in cancer. 
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Constinean and colleagues reported, for the first time, that a miR by itself could 
induce a neoplastic disease (Constinean et al. 2005). In fact, by using a transgenic 
mouse model, they demonstrated that overexpression of miR-155 in B-cell induce 
a lymphoma pre-B leukaemia. Then, Petrocca and colleagues (Petrocca et al. 
2008) have demonstrated that miR106b-25 cluster plays a key role in gastric 
cancer interfering with proteins involved both in cell cycle and apoptosis, whereas 
Johnson have showed that Let-7 family contains miRs that are able to regulate the 
RAS family of oncogenes (Johnson et al. 2005). 
Deregulation of miR expression levels emerges as the main mechanism that 
triggers their loose or gain of function in cancer cells. The activation of the 
oncogenic transcription factor such as Myc, represents an important mechanism 
for altering miRs expression. Genomic aberration such as amplification, 
chromosomal deletions, point mutation or aberrant promoter methylation might 
alter miRs expression. Chromosomal abnormalities can trigger oncogenic action of 
miRs by modulating miR expression in the wrong cell type or at wrong time. 
Several examples of miRs whose expression is deregulated in human cancer have 
been reported. miR-155 is overexpressed in Hodgkin lymphoma, in pediatric 
Burkitt lymphoma and in diffuse large B-cell Lymophoma (Eis et al. 2005, Kluiver 
et al. 2005). MiR-21 is upregulated in breast cancer and in glioblastoma, while 
miR-143 and miR-145 genes are significantly downregulated in colon cancer 
tissue compared with colon mucosa (Micheal et al. 2003). Evidence now indicates 
that the involvement of miRs in cancer is much more extensive that initially 
expected. Studied that investigated the expression of the entire microRNAome in 
various human solid tumours and hematologic malignancies have revealed 
difference in miR expression between neoplastic and normal tissue (Calin et al. 
2005, Pallante et al. 2006; Weber et al. 2006). These studies show that each 
neoplasia has a distinct miR signature that differs from that of other neoplasm and 
that of the normal tissue counterpart. Moreover, it has become clear that some 
miRs are recurrently deregulated in human cancer. In the most case, miRs are 
upregulated or downregulated in all tumours suggesting a crucial role of these 
miRs in tumorigenesis. However, there are some unusual situation: for example 
member of miR-181 family are up-regulated in some cancer, such as thyroid 
(Pallante et al. 2006), pancreatic (He et al. 2005), and prostate carcinoma (Volina 
et al. 2006) but downregulated in others such as glioblastomas and pituitary 
adenomas (Cianfrè et al. 2005, Bottoni et al. 2007).  
In this context we showed that, in glioma cell lines, high expression levels of miR-
21 and -30b/c are needed to maintain the TRAIL-resistant phenotype (Quintavalle 
et al. 2013). Furthermore, in the same cell lines we found that miR-221-222 
overexpression induced an increase in cell migration and invasiveness by 
downregulating the tumor suppressor protein PTPµ (Quintavalle et al. 2012). On 
the contrary in Non Small Cell Lung Cancer (NSCLC) cell lines we demonstrated 
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that miR-212 behave as a tumor suppressor because it negatively regulates the 
antiapoptotic protein PED (Incoronato et al. 2010). 
 
 
 
1.5.3 MiRs in CSCs 
 
 
 
Since MiRs are critical for both cancer and stem cell properties, their role in CSC 
self-renewal is under intense investigations. Recent studies showed that MiRs are 
the major components of acquisition and maintenance of “stemness” of CSCs 
(Zimmerman et al. 2011). It is interesting that several of the MiRs found to control 
CSC properties are MiRs involved in the regulation of Embryonal Stem Cells 
(ESC) self-renewal and differentiation. For example, MiR-371–373 cluster is 
specifically expressed in human ESCs and is involved in stem cell maintenance. 
Recently, this cluster is found upregulated in undifferentiated aggressive 
hepatocellular cancer cells (Cairo et al. 2010), whereas in breast cancer cells, it is 
linked to high aggressiveness and promotes tumor invasion and metastasis by 
targeting CD44 (Hang et al. 2008).  
Usually, MiRs that positively regulated the stemness state are upregulated. For 
instance, MiR-17–92 polycistron is more abundant in leukemic stem cells than in 
non-stem leukemic cells or than in their normal counterpart precursors and 
regulate stem cells by targeting p21, resulting in more proliferative cells (Wong et 
al. 2010). MiR-130b is upregulated in CD133+ liver cancer stem cells compared to 
CD133- cells and promotes liver CSC growth and self-renewal via targeting of 
TP53 (Ma et al. 2010). While ESC-enriched miRs seem to be important in CSC 
functions, miRs able to repress pluripotency of ESC are usually inhibited in CSC. 
For instance, members of the Let-7 family have a role of tumor suppressor by 
targeting K-Ras and cMyc and their expression is repressed in lung, breast, liver 
and head and neck CSCs (Lo et al. 2011, Yuet al. 2011, Kong et al. 2010, yang et 
al 2010). In particular, Let-7 overexpression reduces proliferation, mammosphere 
formation, and the proportion of undifferentiated cells in vitro, as well as tumor 
formation and metastasis in vivo (Yu F et all. 2007). Members of the miR-200 
family are downregulated in CSCs isolated from lung, ovarian, head and neck, 
liver, pancreatic and breast cancer compared to their non-stem cancer counterparts 
(Lo et al. 2011, Wu et al. 2011). As discussed earlier, expression of miR-200 
represses EMT and this process of EMT an important role in the progression of 
cancer by promoting invasion, metastasis (Cannito et al. 2010) and stemness 
phenotype in differentiated cells. (Floor et al. 2011, Kong et al. 2011, Scheel et al. 
2011). In breast cancer, miR-200c targets proteins involved in invasiveness, 
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resistance to apoptosis and induction of breast CSC characteristics (Chang et al. 
2011). 
In addition to the alteration of miR related to embryonal stem-regulation, studies 
demonstrated that miRs involved in the regulation of various adult stem cell 
functions also play important roles in regulation. For instance, miR-125b 
suppresses glioma SC proliferation by targeting CDK6 and CDC25A, thus 
inducing cell cycle arrest in G1 (Shi et al. 2010).  
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2. AIM OF THE STUDY 
 
 
 
Currently, breast cancer represents a worldwide emergence. Although advances in 
classification and standard treatments have improved the life prospective of 
patients, the incidence of death is still high due to recurrence and metastasis. 
Recently, the discovery of a putative CSCs subpopulation has shed new light on 
the conception of tumor. This population is responsible for sustaining the tumor 
growth and, under determinate conditions, can disseminate and migrate to give rise 
to a secondary tumor or metastasis to distant organ. Furthermore CSCs have 
shown to be more resistant to anti-tumor treatments than the non stem cells, 
suggesting that surviving CSCs could be responsible for tumor relapse after 
therapy. These important properties have raised the interest in understanding the 
mechanisms that govern the generation and maintenance of this special population 
of cells. In the last decade it has became clear that miRs are critical players of 
most cellular events, including stem cell and cancer stem biology, and that they 
contribute actively to the regulation of cancer stem cell features such as metastasis 
and response to chemotherapy. 
The present work aims to identify new miRs differentially expressed in cancer 
stem cell compared to differentiated cells and to investigate their role in the 
regulation of key proteins involved in the stemness homeostasis. MiRs act through 
the repression of target genes and the identification of “disregulated miRs” led to a 
deeply comprehension of the aberrant signals that operate in cancer stemness fate. 
The characterization of miRs able to regulate CSC self-renewal should have 
important implications in understanding breast cancer malignancy and behaviors 
as metastasis spread and drug resistance. 
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3. MATERIALS AND METHODS 
 
 
 
3.1 Cells and mammospheres culture 
 
 
 
Breast tumor differentiated cells from three patients (#1, #2,#3) and BTSCs 
(Breast tumor stem cells) have been obtained as previously described by Dontu 
and colleague(Dontu et al. 2003) and have been used for miR array. T47D cells 
were grown in RPMI 1640 Media supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin. 
For mammospheres culture, single cells were plated at a density of 1,000 cells/ml. 
Cells were grown in a serum-free DMEM-F12 (Sigma, Milan Italy), supplemented 
with B27 (Life technologies Milan Italy), 10 ng/ml EGF (Sigma, Milan Italy) and 
20 ng/ml bFGF (BD Biosciences, Milan Italy) and 1X antibiotic-antimycotics 
(Life technologies, Milan Italy). After 5-7 days, mammospheres, appearing as 
spheres of floating viable cells, were collected by gentle centrifugation (800 rpm) 
and dissociated with 0.25% trypsin for 5 min. HEK-293 were grown in DMEM 
Media supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 
U/ml penicillin/streptomycin. 
 
 
 
3.2 Cells transfection 
 
 
 
For miRs transient transfection, cells at 50% confluency were transfected using 
Oligofectamine (Invitrogen, Life technologies Milan Italy) with 100nM of pre-
miR-221, scrambled or anti miR-221 (Ambion, Life technologies Milan Italy). In 
order to overexpress DNMT3b, cells were transfected using Lipofectamine 2000 
with 3 µg of DNMT3b cDNA, a kind gift of Anna Portela (IDIBELL, Barcellona). 
To knock down DNMT3b gene expression, specific DNMT3b siRNA was 
transfected using Lipopfectamin 2000 at a final concentration of 100 nm (Santa 
Cruz Biotechnology, MA). 
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3.3 Virus infection 
 
 
 
Breast primary cell line obtained from patient (patient #5) was infected using 
TWEEN miR-221 or TWEEN control vector as already described by Quintavalle 
(Quintavalle et al. 2012). Briefly, on the day of infection, the medium was 
removed and replaced with viral supernatant with the addition of 4 mg/ml of 
Polybrene. Cells were then centrifuged in their plate for 45 min in a Beckman GS-
6KR centrifuge, at 1800 rpm and 32°C. After centrifugation, cells were kept for 
O/N in a 5% CO2 incubator at 37°C. After exposure, cells were washed twice with 
cold PBS and fresh medium was added. At 48 h after the infection, cells were 
washed with PBS, harvested with trypsin/EDTA and analyzed by FACS for GFP 
expression.  T47D cells were infected with a lentiviral construct overexpressing a 
short hairpin for DNMT3b  (Santa Cruz Biotechnologies, MA). 
 
 
 
3.4 Protein isolation and Western blotting 
 
 
 
Cells were washed twice in ice-cold PBS, and lysed in JS buffer (50 mM HEPES 
pH 7.5 containing 150 mMNaCl, 1% Glycerol, 1% Triton X100, 1.5mM MgCl2, 
5mM EGTA, 1 mM Na3VO4, and 1X protease inhibitor cocktail). Protein 
concentration was determined by the Bradford assay (BioRad) using bovine serum 
albumin as the standard, and equal amounts of proteins were analyzed by SDS-
PAGE (12.5% acrylamide). Gels were electroblotted into nitrocellulose 
membranes (Millipore, Bedford, MA). Membranes were blocked for 1 hr with 5% 
non-fat dry milk in Tris Buffered Saline (TBS) containing 0.1% Tween-20, and 
incubated at 4°C over night with the primary antibody. Detection was performed 
by peroxidase-conjugated secondary antibodies using the enhanced 
chemiluminescence system (Thermo, Euroclone Milan Italy). Primary antibodies 
used were: anti-Zeb-1, anti-Oct-3/4, anti-Nanog, cytokeratin 18, cytokeratin 8 
(Santa Cruz Biotechnologies, MA), anti DNMT3b (Abcam) and anti-bActin 
(Sigma, Milan Italy). 
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3.5 MiR Microarray 
 
 
 
5 µg of total RNA from each sample was reverse transcribed using biotin end 
labeled random-octamer oligonucleotide primer.  Hybridization of biotinlabeled 
complementary DNA was performed on Ohio State University custom miR 
microarray chip (OSU_CCC version 3.0), which contains 1150 miR probes, 
including 326 human and 249 mouse miR genes, spotted in duplicates. The 
hybridized chips were washed and processed to detect biotin-containing transcripts 
by streptavidin-Alexa647 conjugate and scanned on an Axon 4000B microarray 
scanner (Axon Instruments, Sunnyvale, Calif ).  
Raw data were normalized and analyzed with GENESPRING 7,2 software 
(zcomSilicon Genetics, Redwood City, CA). Expression data were median-
centered by using both the GENESPRING normalization option and the global 
median normalization of the BIOCONDUCTOR package (www.bioconductor.org) 
with similar results. Statistical comparisons were done by using the 
GENESPRING ANOVA tool, predictive analysis of microarray (PAM) and the 
significance analysis of microarray (SAM) software(http://www-
stat.stanford.edu/~tibs/SAM/index.html).  
 
 
 
3.6 Breast Primary cell cultures 
 
 
 
Breast ductal carcinoma specimens were collected at surgical Unit of 
ClinicaMediterranea SPA (Naples). All samples were collected according to a 
prior consent of the donor before the collection, acquisition or use of human tissue. 
To obtain the cells, samples were mechanically and enzymatically disaggregated 
and then the lysates were grown in DMEM-F12 medium supplemented with 10% 
FBS 1% penicillin streptomycin and 20 ng/ml EGF (Sigma-Aldrich, Milan Italy). 
To exclude a fibroblast contamination cells were fixed and then stained for Pan 
Keratin and analyzed by Immunohistochemistry.  
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3.7 Mammospheres forming assay  
 
 
 
Mammospheres were resuspended in 0.5% agar (Bacto-Agar, Difco Laboratories) 
and layered on preformed 0.8% agar layer using a 60 mm Petri dishes (BD). 
Colonies were counted under an inverted microscope (Nikon) and then 
photographed. 
 
3.8 RNA extraction and Real-time PCR 
 
 
 
Total RNAs (miR and mRNA) were extracted using Trizol (Invitrogen) according 
to the manufacturer’s protocol. Reverse transcription of total miR was performed 
using miScript reverse Transcription Kit (Qiagen, Milan Italy), for mRNA was 
used SuperScript® III Reverse Transcriptase (Life Technologies). Quantitative 
analysis of Nanog, Oct3/4 Sox2, Actin (as an internal reference), miR-221, and 
RNU6B (as an internal reference) were performed by Real time PCR using 
specific primers (Qiagen), miScript SYBR Green PCR Kit (Qiagen), and iQTM 
SYBR Green Supermix (Biorad), respectively. Experiments were carried out in 
triplicate for each data point, and data analysis was performed by using software 
(Bio-Rad). 
 
 
 
3.9 Luciferase assay 
 
 
 
The 3’ UTR of the human DNMT3b gene was PCR amplified using the following 
primers: DNMT3b-Fw:5’GCTCTAGACAGCCAGGCCCCAAGCCC3’; 
DNMT3b-Rv: 5’GCTCTAGAACCTCAGGCTACCCCTGC3’, and cloned 
downstream of the Renilla luciferase stop  codon in pGL3 control vector 
(Promega, Milan Italy). An inverted sequence of the miR-binding sites was used as 
negative control. HEK-293 cells were co-transfected with 1.2µg of plasmid and 
400 µg of a Renilla luciferase expression construct, pRL-TK (Promega, Milan, 
Italy), with Lipofectamine 2000 (Invitrogen, Milan, Italy). Cells were harvested 24 
hrs post-transfection and assayed with Dual Luciferase Assay (Promega, Milan, 
Italy) according to the manufacturer’s instructions. Three independent experiments 
were performed in triplicate.  
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3.10 RNA extraction and Real time PCR  
 
 
 
Total RNA (miR and mRNA) was extracted using Trizol (Invitrogen, Milan, Italy) 
according to the manufacturer’s protocol. Reverse transcription of total miR was 
performed starting from equal amounts of total RNA/sample (1µg) using miScript 
reverse Transcription Kit (Qiagen, Milan, Italy), and with SuperScript® III 
Reverse Transcriptase (Invitrogen, Milan Italy) for mRNA. Quantitative analysis 
of Nanog, Oct3/4, DNMT3b, β-actin (as an internal reference), miR-221, miR-
222, and RNU5A (as an internal reference) were performed by Real time PCR 
using specific primers (Qiagen, Milan, Italy), miScript SYBR Green PCR Kit 
(Qiagen, Milan, Italy), and iQTM SYBR Green Supermix (Bio-Rad, Milan, Italy), 
respectively. The reaction for detection of mRNAs was performed as follows: 
95°C for 15’, 40 cycles of 94°C for 15’’, 58°C for 30’’, and 72°C for 30’’. The 
reaction for detection of miRs was performed as follows: 95°C for 15’, 40 cycles 
of 94°C for 15’’, 55°C for 30’’, and 70°C for 30’’. All reactions were run in 
triplicate. The threshold cycle (CT) is defined as the fractional cycle number at 
which the fluorescence passes the fixed threshold. For relative quantization, the 2(-
Δ
CT) method was used as previously described [26]. Experiments were carried out 
in triplicate for each data point, and data analysis was performed by using a Bio-
Rad software (Bio-Rad, Milan, Italy). 
 
 
 
3.11 FACS analysis 
 
 
 
Cells were stained with PE anti-CD24- and anti- CD44-PerCPCy 5.5 or with 
negative control PE-conjugated and PerCPCy 5.5-conjugated antibody (BD). After 
enzymatic detachment from saturated cultures, cells were counted, resuspended in 
the analysis buffer at 2x104 for 100µl and stained by incubation at 4°C for 20 
minutes with the appropriate amount of above mentioned MoAbs. After staining, 
all samples were washed twice with PBS solution, centrifuged and resuspended in 
0.1 ml of PBS for FACS analysis.  The negative control was prepared to exclude 
the signal background caused by the cellular autofluorescence. 
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4. RESULTS 
 
 
 
4.1 MiRs involved in stemness property 
 
 
 
To identify miRs differentially expressed in BCSCs and involved in stemness 
maintenance, we performed a microarray analysis. To obtain a data that was more 
related to the “physiological/pathologial condition”, we used primary cell line 
obtained by three patients’ speciements (Fig 13). Briefly, biopsies were 
enzymatically disaggregated and epithelial cells were seeded in two different 
conditions. In the first, the cells were classically seed in adherence condition and 
grown in medium containing FBS. In the second, cells were grown using the 
culture system adopted by Dontu and colleagues (Dontu et al. 2003). Cells were 
grown in ultra-low attachment flasks, using a medium without serum but 
implemented with EGF and FGF growth factor. This system allows to isolate and 
propagate in vitro breast stem/progenitor cell as non-adherent spherical clusters, 
termed ‘mammospheres’. Instead, in these conditions, only the cells able to be 
resistant to anoikis and responsible to EGF and FGF growth factors are able to 
survival and these characteristics are both exhibit by stem/progenitors cells. All 
this procedure was done in collaboration and under the supervision of 
MatildeTodaro and Girogio Stassi (Department of Surgical and Oncological 
Sciences, University of Palermo). 
 
 
 
 
 
Figure 13: Biopsy disaggregation. Suspension culture is a strategy for the in vitro enrichment and 
propagation of human mammary stem /progenitor cells. 
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To confirm that these cells were really enriched for stem/progenitors cells, we 
analyzed the expression of some stem markers. These markers are normally 
express in embryonic cells, sustaining self-renewal, but their expressions have 
been observed also in several cancer stem populations. In particular, we analyzed 
the expression of Nanog, and Sox2 that usually are more expressed in cancer stem 
cells than differentiated counterpart. We confirmed, by Real time-PCR that the 
“putative stem culture” isolated from patients, expressed high levels of these genes 
respect to the differentiated cells in all three patients derived cell lines (Figure 14). 
Then, we moved on with the analysis of the global miR expression profile that 
characterizes breast stem cells population. 
 
 
 
 
 
 
Figure 14: Real time-PCR of Nanog and Sox2 in primary cell populations. Nanog and Sox2  
are over-expressed in cancer stem cells than differentiated cells. Representative of at least three 
independent experiments. 
 
 
 
The array was performed analyzing the miR expression profile of primary BCSCs 
compared to the expression profile of the breast cancer cells growing in adherence 
(differentiated cells). The analysis was performed with a microarray chip 
containing 1150 miR probes, including 326 human and 249 mouse miRs, spotted 
in duplicates. The microarray results revealed a significant up-regulation of three 
miRs in cancer stem cells (miR-221, miR-24 and miR-29a) (Table 1) and a down-
regulation of other miRs (miR-216a, miR-25, and let-7d). We focused our 
attention on miR-221 since its role in tumorigenesis was already reported in 
several tumor types (Quintavalle et al. 2011,Garofalo et al. 2008, Visone et al. 
2007). Through a Real time-PCR on the same samples, we validated the 
microarray results and confirmed that miR-221 was upregulated in the stem cells 
populations respect to the differentiated cells. This finding led us to hypothesize 
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that the expression of those miR can be functional to the maintenance of stemness 
phenotype in BCSCs (Figure 15). 
 
 
 
Unique id  Parametric p-value Fold change (stem vs 
differentiated) 
Hsa-miR-221 0,013 1,8 
Hsa-miR-24 0,003 2,55 
Hsa-miR-29a 0,023 2,47 
Hsa-miR-25 0,001 -1,89 
Hsa-miR-216a 0,003 -2,46 
let-7d 0,004 -1,4 
 
Table 1. All miRs differentially express have p value 0,05. 
 
 
 
 
 
 
Figure 15. MiR-221 expression levels is higher in breast cancer stem cells of patient than 
differentiated cells. Relative expression of miR-221 was calculated using the comparative CT 
methods. Representative of at least three independent experiments. 
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4.2 T47D mammospheres culture is enriched of mammary stem progenitors 
and express high levels of miR-221 
 
 
 
To uncover the effect of miR 221 on the stemness properties, we adopted a 
suspension culture of T47D breast cancer cell line. We chose a tumor cell line as 
an easy and reproducible model for the identification of those miRs involved in 
stemness functions. As well as for primary cells described before, T47D cells were 
seeded in non-adherent conditions and using a medium supplemented with EGF, 
b-FGF, B27. This system allows isolating CSCs present in to the T47D population 
as classical mammosphers clusters (Figure 16). We investigated the expression of 
stemness genes and EMT markers associated with the stem-like phenotype to 
verify the reliability of the method. We chose Sox2, Nanog, and Oct3/4 as 
stemness markers and E-cadherin and Zeb1 as EMT markers. As expected for a 
stemness phenotype, we found an upregulation of Zeb-1, Oct3/4 Nanog but a 
decrease of expression of E-cadherin, a repressor of EMT transition. Moreover, we 
evaluated also the levels of Cytokeratin 18 and 8, known structural proteins that 
regulate the epithelial structure of luminal cells. After 7 days of culture, by 
Western blot we observed that the levels of these two additional markers resulted 
downregulated in suspension-stem like cultures (Figure 17A and B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. T47D suspension culture. The growth of T47D in non-adherent condition allow to 
isolate cluster of cells called “mammospheres”. 
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B 
 
 
 
Figure 17. T47D suspension culture is enriched for stem cells/progenitors stem. 
(A) Zeb1, Oct3/4, Slug, Nanog, Ck8, 18, E-cadherin levels were evaluated by immunoblotting. To 
confirm equal loading, the membrane was immnunoblotting with anti b-actin antibody. (B) Nanog 
and Oct3/4 for were also evaluate through Real time PCR together with Sox2. Representative of at 
least three independent experiments **
 
These data confirm that the mammospheres culture of T47D can be used as a tool 
to obtain population enriched of stem/progenitors that express higher level of gene 
involved in the positive modulation of the stemness state and lower genes of those 
involved in epithelial phenotype.  
Next, we found that the levels of miR-221 was increased also in T47D stem cells 
population in a similar manner to primary breast cancer cells line (Figure 18).  
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Figure 18: miR-221 levels are higher also in T47D stem cells. 
 
 
 
 
4.3 MiR-221 and stemness 
 
 
 
To address the biological role of miR-221 in BCSCs’ behaviour, we modulated the 
levels of miR-221 through transfection and looked for T47D mammospheres 
formation in non-adherent conditions. After 3 or 6 days of culture in stem medium, 
we found that miR-221 overexpression increased the number of mammospheres 
compared to the scrambled oligonucleotide (control) (Figure 19A). 
 
A    B 
      
  
 
Figure 19. miR-221 expression induces the switch on pathway involved in stemness 
phenotype. (A) T47D transfected with miR-221 were grown in non-adherent conditions. 
Mammospheres are counting after 3 and 6 days. (B) Effect of miR transfect in T47D differentiated 
cells on Oct3/4, Slug and Nanog expressions 
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To evaluate whether miR-221 may directly affect the pathways involved in 
stemness maintenance, we transfected miR-221 in T47D differentiated cells and 
analysed by Western blot, the levels of the stem cells markers. As shown in Figure 
18B, Nanog, Oct3/4 and Slug were upregulated upon miR-221 expression. 
Therefore, this data indicated that miR-221 expression trigger the switch on 
pathway involved in stemness phenotype. To further confirm our observations, we 
infected a primary breast cell line obtained from patient’s specimen (patient #5) 
with a lentiviral construct encoding for miR-221. As shown in Figure 20A the 
infection resulted in miR-221 over-expression as assessed by qRT-PCR (Figure 
20B). Thank to the stable expression of miR-221 over the time, we performed a 
replating assay in which the formed “primary” mammospheres were dissociated 
into single cells and grown as “secondary” mammospheres. We observed that cells 
overexpressing miR-221 showed increased spheres formation capacity (Figure 
20B) that was enhanced upon first stem spheres replating (Figure 20C), indicating 
an expansion of stem cells population respect to the control. Interestingly, this 
stably over-expressing miR-221 cells also showed an enrichment in CD44+/CD24- 
marker that is known to represent the signature of breast cancer stem cells (Figure 
21). 
 
 
 
 
A    B        C 
 
 
 
Figure 20. MiR-221 stably expression affect the capacity of primary breast cancer to form 
primary and secondary mammospheres respect to the tween control. (A) miR-221 
constitutiveexpression was evaluated through Real time PCR. Primary cells infected were seed in 
non-adherence condition (B) and after a week were disaggregated and replated to obtain secondary 
mammospheres (C). 
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Figure 21. Primary cells stably infected with a lentivirus encoding for miR-221. 
Overexpression of mir-221 in primary cells induces an upregulation of CD44 marker levels and a 
downregulation of CD24 respect to the Tween control. 
 
 
 
4.4 Identification of DNMT3b as a new target of miR-221 
 
 
 
We then investigated miR-221 targets possibly involved in the stemness 
phenotype. Among the potential targets predicted by bioinformatics analysis 
programs, we found that the protein DNMT3b, a DNA methyltrasferase involved 
in de novo DNA methylation, was predicted as a target of miR-221. The most 
widely used approach for experimentally validating miR target is to clone the 
predicted miR-binding sequence downstream of a luciferase report construct, and 
to cotrasfected it with a miR of interest in a luciferase assay. To this end we cloned 
the 3’UTR sequence of human DNMT3b into the luciferase expressing vector 
pGL3-control downstream of the luciferase stop codon; HEK-293 cells were 
transiently transfected with this construct in the presence of pre miR-221 or in the 
presence of a scrambled oligonucleotide acting as negative control. As reported in 
Figure 22, miR-221 significantly reduced luciferase activity compared to the 
scrambled oligonucleotide. This indicated that miR-221 binds the 3’UTR of 
DNMT3b and impair its mRNA translation. In order to determine that the region 
was specific for the binding with miR-221, we generated a mutant, in which the 
seed sequence was cloned with an inverted orientation, lacking in this manner of 
the binding site. As shown in figure 22, miR-221 did not significantly reduce 
CD24 
CD44 
tween miR-221 
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luciferase activity in the presence of the 3’ UTR-DNMT3b mutated sequence. This 
result indicates that miR-221 targets DNMT3b mRNA. 
 
 
 
 
 
 
Figure 22: Identification of target site in 3’UTR of DNMT3b. Complementary site for miR-221 
on wild type DNMT3b 3’UTR. For luciferase activity HEK293 cells were transiently cotransfected 
with the luciferase reporter containing wild type DNMT3b-3’UTR or DNMT3b mutant in the 
presence of miR-221 or a scrambled oligonucleotide. Luciferase activity was evaluated 24h after 
transfection as described in Material and Methods. Representative of at least three independent 
experiments. 
 
 
 
4.5 MiR-221 specifically represses DNMT3b expression  
 
 
 
In order to find a causative effect between miR-221 and DNMT3b expression, we 
transfected T47D with a pre-miR-221 for 48 hrs and then analyzed DNMT3b 
levels by Western blot and qRT-PCR. After transfection, we found that both 
DNMT3b protein and mRNA levels were downregulated (Figure 23 A-B) 
confirming that DNMT3b mRNA is targeted by miR-221. In contrast, T47D 
transfected with an antimiR-221, showed an increase of DNMT3b protein and 
mRNA (Figure 23 C-D).  
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A        B                   C            D 
 
 
 
 
Figure 23. DNMT3b and miR-221 expression levels are inversely correlated in T47D stem 
cells. Effect of miR-221 or Anti-miR-221 transfection on DNMT3b expression: miR-221induced a 
decrease of DNMT3b mRNA (A) and protein (B) if compared to the scrambled sequences. On the 
contrary, anti miR-221 was able to increase DNMT3b expression levels (C-D). 
 
 
 
 
To assays whether the expression of miR-221 was inversely correlated with 
DNMT3b also in T47D mammospheres, we analyzed the levels of the protein in 
stem and differentiated T47D cells. As shown in Figure 24 A and B, we found a 
reduced DNMT3b expression in T47D stem cells. Furthermore, we observed the 
same decrease of DNMT3b mRNA levels also in stably expressing miR-221 
primary cells (Figure 24C).  
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A      B 
 
                       
 
 
 
C 
 
 
 
Figure 24. DNMT3b is inversely correlated with miR-221. DNMT3b is expressed at lower 
levels in T47D stem cells (A-B) and primary cells that overexpressing miR-221 rispect to the 
controls (C). 
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4.6 MiR-221 control stem proprieties through DNMT3b 
 
 
 
DNMT3b is a master regulator of Nanog and Oct3/4 expression and, through its 
methylation activity, is able to repress their expression during embryogenesis. 
Therefore we wondered whether the up-regulation of Nanog and Oct3/4 observed 
upon miR-221 expression was related to the down regulation of DNMT3b levels 
and consequently to its reduced methylation activity. We transfected T47D with a 
DNMT3b cDNA and investigated the effect on stem markers expression and 
mammospheres formation. As shown in Figure 5, DNMT3b was able to inhibit the 
expression of Nanog and Oct3/4 as well as mammospheres formation (Figure 
25A-B). To confirm the direct implication of DNMT3b in stemness maintenance, 
we transfected T47D with a siRNA to obtain a transient silencing of DNMT3b 
(Figure 25C-D) and observed an increase of mammosphere formation in cell 
silenced for DNMT3b, mimicking the effect of miR-221 on mamospheres 
numbers. These data confirmed our hypothesis of an involvement of DNMT3b in 
the stemness properties. 
MiRs may target different proteins. In order to demonstrate that stemness features 
observed by miR-221 overexpression were carried out by miR induced DNMT3b 
downregulation, we performed a rescue experiment transfecting simultaneously 
pre miR-221 and a DNMT3b cDNA lacking of 3’UTR in T47D cells. As shown in 
Figure 25 A-B, the effect of the miR-221 on Nanog and Oct3/4 expression was 
abolished by the overexpression of DNMT3b cDNA. The simultaneous expression 
of DNMT3b protein was also able to partially revert the miR-221 effect on 
mammaspheres formation. This rescue experiment provides the causative 
connection between miR-221 expression, DNMT3b down regulation and stemness 
phenotype.  
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A          B 
 
 
 
 
C          D 
 
 
 
 
Figure 25. MiR-221 regulates stemness properties by targeting DNMT3b. (A) DNMT3b is able 
to repress stem marker and mammospheres formation as assessed by mammospheres counting 
assay (A) and Western blot. (B) DNMT3 silencing mimics the effect of miR-221 on stemness 
properties (C-D).    
 
 
 
Furthermore, we stably infected T47D with a lentiviral construct overexpressing a 
short hairpin for DNMT3b and observe an increasing ability of mammospheres 
formation in DNMT3B silenced T47D cell lines, and that this effect is enhances 
after the first replating. This experiment testify that DNMT3b silencing determine 
a progressive expansion of the stem cells compartment, in a similar way to the 
primary cell line stably expressing the miR-221 (Figure 26). 
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Figure 26. Analysis of serial mammospheres formation. T47D infected with a lentivirus 
encoding for a short hairpin for DNMT3b formed more primary (MS1) and secondary (MS2) 
mammospheres respect to the control. 
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5. DISCUSSION 
 
 
 
The CSC model suggests that cancers arise from cells that can be defined, by 
analogy with totipotent stem cells, as cancer stem cells (CSCs) displaying self-
renewal and differentiation potentials, to give rise to the phenotypically diverse 
cancer cell populations. However, little is known about what regulates their critical 
ability to self renewal and initiate tumors. 
In less than 10 years, miRs have experienced a radical shift in people’s mind, once 
considered as junk RNA not useful for the individual, they now appear as critical 
regulators of most cellular events. By their ability to target hundreds of mRNAs, 
they can induce a rapid switch in cell fate and fine tune genome expression and are 
now accepted as major post-transcriptional regulators. In the last years researchers 
showed that miRs regulate target genes involved in key cellular processes as well 
as stem cell biology. Interestingly, some miRs regulating ESCs are found 
important in regulating the CSC phenotype, suggesting that their alteration can 
contribute to maintain or trigger a stem-phenotype in cancer cells. Indeed ESC-
enriched miRs such as miR-17–92 cluster, miR-371–373 cluster or miR-130 
induce “stemness” and aggressiveness in cancer cells, while let-7 and miR-200 
inhibit CSC properties (Wong et al. 2010, Wu et al. 2011).  
Breast cancer is the leading cause of death in woman and is characterized by an 
elevated heterogeneity, different responses to therapies and metastatic variability 
among patients. Advances in standard treatment of this disease, such as surgery, 
radiotherapy and chemotherapy have increase patients survival, but the incidence 
and the death related to this cancer are still high. Breast cancer is the first human 
carcinoma for which a putative cancer stem cell subpopulation has been isolated at 
the basis of its CD44+/CD24-/low antigenic phenotype (Al-Hajj et al. 2003). 
Actually, breast cancer stem cells are objected of several studies because they are 
considered as the driving force of tumor and the understanding the molecular 
characteristics that govern their stemness could represent a therapeutic promise to 
erase the cancer.  
In this study, we identify miR-221 as important player in the regulation of the 
cancer stem cells homeostasis and a new mechanism by which miR-221 is able to 
hold on the stemness state of cancer cells.  
In order to identify new miRs that could act as molecular switchers in the 
maintenance of stemness properties, we investigate miR expression profile in 
breast cancer stem cells compared to their differentiated counterparts. We 
identified three miRs upregulated in breast cancer stem cells and three 
downregulated. Among the different miRs, we focus our attention on miR-221. 
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We found that miR-221 is expressed at higher levels in stem population of both 
primary and T47D cell lines compared to differentiated cells.  
We focused on miR-221 because its expression in human cancer has been 
extensively investigated (Garofalo et al 2009, Visone et al 2007). MiR-221 has 
been frequently found overexpressed in a number of human tumors (Pallante et al 
2006, Conti et al 2009, Pineau et al 2010) and is commonly identify as an 
oncomiR thanks to its ability to regulate cancer development and progression. For 
instance, we found that miR-221 increase cell migration and invasiveness in 
glioma cells (Quintavalle et al. 2012) and that is able to induce DNA demage, 
conferring oncogenic traits. (Quintavalle et al. 2013). Interestingly, the 
upregulation of miR-221 was reveled in breast cancer cells resistant to the 
tamoxifen and fulvestrant (Rao X et al. 2010) and other authors demonstrated that 
it was involved in the promotion of an aggressive basal-like phenotype triggering 
EMT process (Maitri Y Shah 2011). Since EMT is a process that is usually 
associated with a cancers stemness phenotype, we hypothesize that miR-221 can 
be part of a more complex signaling that governs the stemness properties. In 
agreement with this hypothesis, we found that miR-221 is able to induce the 
expression of Slug, Nanog, Oct3/4 genes, which enforce the stemenss state. 
Interestingly, the re-expression of pluripotency associated genes and adult stem 
cell gene expression signature in cancer cells, as well as the upregulation of EMT 
correlates with poor prognosis and with resistance to chemotherapy. In addition, 
miR-221 has an impact on the expansion of the cancer stem cells compartment in 
T47D cells, justified by an increasing of mammospheres number. MiRs have an 
important role in regulating expression profile by repressing the translation of 
selected mRNAs. In this manner, they can act on multiple pathways and influence 
several biological processes. Therefore, we wonder if the up-regultion of miR-221 
could be functional in regulating self-renewal and differentiation signaling of 
cancer stem cells. We looked for possible target involved in the regulation of self-
renewal and differentiation processes and focuses our attention on DNMT3b as 
putative target gene. DNMT3b is a de novo DNA methyl transferase and its 
involvement in stemness regulation derived our hypothesis. In fact it is known that 
epigenetic mechanisms are involved in the regulation of the embryonic and adult 
stem cell transcriptional program, controlling self-renewal and differentiation. 
Multiple observations indicate that the establishment and maintenance of CSC 
features can be orchestrated by a similar way. DNMT3b has been described to be 
able to methylate and consequently repress Nanog and Oct3/4 gene during 
embryogenesis. In embrionic stem cells, Nanog is involved in a complicated 
stemness regulatory network in cooperation with other key transcriptional factors, 
such as Oct3/4, Sox2, and Lin 28, to precisely balance between pluripotency and 
differentiation tendency (Kalmaret al. 2009). During tumorigenesis, some 
embryonic genes may be re-expressed or activated and influence the tumor 
** 56*
features and contribute to generate new cancer stem cells. For instance, the 
upregulation of Nanog and Oct3/4 regulates several aspects of cancer development 
such as tumor cell proliferation, self-renewal, motility, epithelial-mesenchymal 
transition, immune evasion, and drug-resistance, which are all defined features for 
cancer stem cells (Ibrahim et al. 2012, Chiou et al. 2010, Lin et al. 2012, Noh et al. 
2012). Functional studies have demonstrated that Nanog  and Oct3/4 are not only a 
CSC marker, but also promote CSC-like characteristics in several cancers. For 
example, ectopic overexpression of the Nanog gene in prostate cancer cells 
enhanced clonal growth and tumor regenerative capacity (Jeter et al. 2011), and 
the activation of embryonic Nanog gene drives a subpopulation of colorectal 
cancer cells to adopt a stem-like phenotype (Ibrahim et al. 2012). In addiction, 
overexpression of Nanog, along with Oct3/4, increased clonogenic growth and 
spheroid body formation of lung adenocarcinoma cells (Chiou et al. 2010). On the 
basis of these data, we hypothesized that miR-221 promote stemness features by 
downregulating DNMT3b and consequently Nanog and Oct3/4 gene methylation 
status (Li et al. 2007, Wongtrakoongate et al. 2014). We provided for the first time 
evidence that miR-221 is able to down-regulate DNMT3b expression levels and 
that its down regulation affects the breast cancer stem cell behaviour. In fact, 
DNMT3b siRNA is able to enhance the capability of T47D cells to form 
mammospheres and to up-regulate Nanog and Oct3/4 respect to the control. We 
also demonstrated that the endogenous levels of DNMT3b are lower in T47D 
mammospheres than adherent cells. These findings confirmed the inverse relation 
between miR-221 and DNMT3b in breast cancer stem cells. Because miRs can 
affect many different proteins, we validated the effect of dnmt3 by costrasfecting 
of miR-221 and ectopic DNMT3b lacking the miR binding sites in its 3’UTR. This 
rescue experiment provided the causative link between miR-221, DNMT3b and 
stemness. The idea that DNMT3 can act repressing the stemness properties is in 
agreement with Challen’s work. Challen and colleagues demonstrated that the 
deletion of Dnmt3a (member of the family) in hematopoietic stem cells show a 
dramatic expansion of the stem cell compartment, in secondary but not primary 
transplants (Challen et al. 2011). Moreover, despite a marked expansion of 
stem/progenitor cells, Dnmt3a deficient cells did not show a parallel increase in 
contribution to differentiated hematopoietic lineages, suggesting a differentiation 
defect. Since DNMT3b and DNMT3a have similar sequence and function, it 
possible postulate that dnmt3b downregulation mediated by miR-221 could affect 
the expansion of breast cancer stem cells compartment upregulating Nanog and 
Oct3/4 and consequently altering the differentiated phonotype. On the basis of our 
results, we can hypothesize that DNMT3b plays a negative role on breast cancer 
stemness and can be considered as a tumor suppressor gene. However, the role of 
DNMT3b in cancer development is not really clear. Early works demonstrated that 
DNMT3b was overexpressed in several tumors (Esteller et al. 2007, Robertson et 
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al. 1999) and that its overexpression correlated with tumorigenesis and with the 
methylation of specific groups of genes, usually belong to tumor suppressor genes 
(Esteller et al. 2007, Issa et al. 2004, Roll et al. 2008). In particular, DNMT3b is 
required for the survival and proliferation of human lung, breast, colon, and 
bladder cancer cells and in lung cancer contributes to the malignant transformation 
induced by SV40T antigen (Soejima et al. 2003). Although these studies point to 
an oncogenic role of DNMT3b in cancer, the discovery of genetic alteration of this 
gene suggests that its role in cancer is more complex than it was previously 
believed. In fact in samples from patient with immunodeficiency, centromere 
instability and facial anomalies (ICF), whole genome bisulfite sequencing 
identified global loss of DNA methylation associated with genetic defect in 
DNMT3b (Heyn et al. 2012). Usually, a global loss of DNA methylation is 
observed is several tumors and the alterations identified in DNMT3b gene could 
explain the open chromatin that charachterized the cancer stem cells. Nevertheless, 
recent publications have shown that this enzyme also suppresses tumorigenesis. 
Using a conditional DNMT3b knockout in APCMIN- mice, Lin and collegues 
demonstrated that DNMT3b is involved in the transition stage between 
microadenoma formation and macroscopic colon tumor (Lin et al. 2006). Another 
study demonstrated that the conditional knockout of DNMT3b in a mouse model 
of myc-induced lymphomagenesis, increases cellular proliferation. The antitumor 
action of DNMT3b in this model suggested to be mediated by its role in 
maintenance DNA methylation of the putative oncogene MET (Hlady et al. 2012).  
On the basis of these considerations, although DNMT3b was classically 
considered as oncogene due to its role in the hypermethylation of tumor suppressor 
genes, DNMT3b is now considered behave also as tumor suppressor in advanced 
tumor stage. So, DNMT3b can act as tumor suppressor or promoter depending on 
the stage, but it is not excluded that it can have a bivalent role also depending on 
the tumoral cells populations. In stem context, we postulate that DNMT3b activity 
could be not helpful because it can methylate and repress master gene involved in 
the control of stemness state. On the other hand, its expression in differentiated 
compartment can be an advantage and responsible for the methylation of tumor 
suppressor genes that inhibit the growth and aggressiveness of the cancer. 
Therefore, we can hypothesize that DNMT3b perform a double function and that 
its tumor suppressor function could occur in an advance step of tumorigenesis. In 
fact at this stages, its silencing could be an advantage for the cancer because could 
determine an expansion of stem cells compartment and consequently promote a 
greater aggressiveness of the tumor. According with this supposition, it was 
demonstrated that DNMT3a deletion in a lung cancer model promoted tumor 
progression but not initiation, and resulted in anchorage-independent growth and 
expression of metastasis-associated genes in breast cancer cell lines (Quing et al. 
2011).  
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In conclusion, we have shown a potential involvement of miR-221 in the 
regulation of stemness features targeting DNMT3b. We identified a new 
mechanism by which miR-221 can influence the tumor characteristic and 
aggressiveness, adding a new piece in understanding the oncogenic mechanism of 
action of miR-221. 
Future therapeutic interventions that target miRs acting as stemness inducer or 
suppressor, should be useful to target key pathways that regulate the stemness state 
of breast cancer cells. This is a rapidly emerging field in oncology and might 
represent a promising strategy for cancer therapy in the future. Therefore, targeting 
the stemness-like properties of cancer cells with agents that modify the expression 
of miR-221 can contribute to reduce the number and to the sensitization of CSCs 
to chemotherapy, impeding tumor relapse.  
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6. CONCLUSIONS 
 
 
 
In this work, we described a new circuit of both genetic and epigenetic 
mechanisms that contributes to the acquisition and maintenance of self-renewal 
and stemness features by breast cancer stem cells. In this study, we show a 
potential involvement of miR-221 in the regulation of stemness features. We 
demonstrated that miR-221 act as a stemness promoter inducing indirectly the 
expression of key genes, Nanog and Oct3/4 and promoting the expansion of stem 
cells numbers. Our data showed that this mechanism is, in part, mediated by 
targeting the DNA methytransferase DNMT3b. The down regulation of this 
enzyme led to the upregulation of Nanog and Oct3/4 genes and to a positive effect 
on the expansion of the stem cells compartment.  
In this manner, we identify a new loop by which miR-221 can influence the 
stemness phenotype of breast cancer stem cells, adding a new information in 
understanding the oncogenic role of miR-221 in breast cancer.  
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ORIGINAL ARTICLE
Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in
glioma cells
C Quintavalle1,2,7, E Donnarumma3,7, M Iaboni1,2, G Roscigno1,2, M Garofalo4, G Romano3, D Fiore1, P De Marinis5, CM Croce4
and G Condorelli1,2,6
Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in
treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show
that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that
these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated
with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the
30 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on
TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression
levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising
therapeutic targets for TRAIL resistance in glioma.
Oncogene advance online publication, 10 September 2012; doi:10.1038/onc.2012.410
Keywords: glioblastoma; TRAIL; therapy; microRNA; treatment; apoptosis
INTRODUCTION
Glioblastomas are the most common primary tumors of the brain
and are divided into four clinical grades on the basis of their
histology and prognosis.1 These tumors are highly invasive, very
aggressive and are one of the most incurable forms of cancer in
humans.2 The treatment strategies for this disease have not
changed appreciably for many years, and failure of treatment
occurs in the majority of patients owing to the strong resistant
phenotype. Therefore, the development of new therapeutic
strategies is necessary for this type of cancer.
A novel interesting therapeutic approach is the reactivation of
apoptosis using member of TNF (tumor necrosis factor)-family, of
which the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) holds the greatest interest. Apoptosis is a particularly
desirable treatment outcome, as it eradicates cancer cells without
causing a major inflammatory response, which could provide
unwanted survival signals. However, many cancers develop
functional defects in the drug-induced apoptosis pathway, which
may lead to constitutive or acquired resistance. To this end,
alternative pathways, such as the one activated by death
receptors including Fas/Apo-1, or DR4 (TRAIL-R1) and DR5
(TRAIL-R2), are being explored for cancer treatment. TRAIL is a
relatively new member of the TNF family, known to induce
apoptosis in a variety of cancers.3 Treatment with TRAIL induces
programmed cell death in a wide range of transformed cells, both
in vivo and in vitro, without producing significant effects in normal
cells.3,4 Therefore, recombinant TRAIL or monoclonal antibodies
against its receptors (TRAIL-R1 and TRAIL-R2) are in phase II/III
clinical trials for different kinds of tumors, either as a single agent
or in combination with chemotherapy.5,6
However, a significant proportion of human cancer cells are
resistant to TRAIL-induced apoptosis, and the mechanisms of
sensitization seem to differ among cell types. Different studies
relate resistance to TRAIL-induced cell death to downstream
factors. It has been shown that downregulation of two anti-
apoptotic proteins such as PED (Phosphoprotein enriched in
diabetes) or cellular-FLICE such as inhibitory protein (c-FLIP)
can sensitize cells to TRAIL-induced apoptosis.7–9 However the
mechanism of TRAIL resistance is still largely unknown.
miRs are a class of endogenous non-coding RNA of 19–24
nucleotides in length that has an important role in the negative
regulation of gene expression blocking translation or directly
cleaving the targeted mRNA.10 miRs are involved in the
pathogenesis of most cancers.10 In the last few years, our
understanding of the role of miRNA has expanded from the
initially identified functions in the development of round worms
to a highly expressed and ubiquitous regulators implicated in a
wide array of critical processes, including proliferation, cell death
and differentiation, metabolism and, importantly, tumorigenesis.11
We have recently showed an important role of microRNAs in TRAIL
sensitivity in non-small cell lung cancer (NSCLC).12–14
In this study, to identify novel mechanisms implicated in TRAIL
resistance in human glioma, we performed a genome-wide
expression profiling of miRs in different cell lines. We found
that miR-30b/c and -21 are markedly upregulated in TRAIL-
resistant, and downregulated in TRAIL-sensitive glioma cells.
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Our experiments indicate that miR-30b/c and -21 modulate TRAIL
sensitivity in glioma cells mainly by modulating caspase-3 and
TAp63 expression and TRAIL-induced caspase machinery.
RESULTS
Selection of TRAIL-sensitive vs TRAIL-resistant glioma cell lines
We analyzed TRAIL sensitivity of different human glioma cell lines.
Cells were exposed to TRAIL at two different concentrations for
24 h and cell death was assessed using the MTT assay (Figure 1a)
or propidium iodide staining (Figure 1b). As shown in Figure 1, we
can distinguish two sets of cells: TB10, LN229, U251 and U87MG
cells exhibited total or partial TRAIL resistance, whereas T98G and
LN18 cells underwent TRAIL-induced cell death.
miRs expression screening in TRAIL-resistant vs TRAIL-sensitive
glioma cell lines
To investigate the involvement of miRs in TRAIL resistance in
glioblastoma cell lines, we analyzed the miRs expression profile in
the most TRAIL-resistant glioma cells (TB10 and LN229) vs the
TRAIL-sensitive cells (T98G and LN18). The analysis was performed
with a microarray chip containing 1150 miR probes, including 326
human and 249 mouse miRs, spotted in duplicates. Data obtained
indicated that seven miRs (miR-21, -30b, -30c, -181a, -181d, -146
and -125b) were significantly overexpressed in resistant glioma
cells with at least 41.9-fold change (Table 1). Quantitative real-
time-polymerase chain reaction (qRT–PCR) validated the micro-
array analysis (data not shown).
Role of miRs in TRAIL resistance in glioma
To test the role of these overexpressed miRs in TRAIL sensitivity in
glioma, we transfected T98G TRAIL-sensitive cells with miR-21,
-30b, -30c, -181a, -146 and -125b. TRAIL sensitivity was evaluated
by MTT assay, propidium iodide staining and colony assay. We
obtained significant results only for miR-30b/c and miR-21 that
were then extensively investigated. In fact, data obtained with
MTT assay and FACS analysis showed that the overexpression of
miR-30b/c and -21 was able to revert TRAIL sensitivity in T98G
(Figures 2a and b). Similar results were obtained in LN18 cells
(Figures 2c and d). This effect was not restricted to glioma, as
miR-30 and miR-21 were able to exert an anti-apoptotic action
also in non small cell lung cancer (NSCLC) (Supplementary
Figure 3B). We further evaluated TRAIL sensitivity by colony assay.
T98G and LN18 cells were transfected with miR-scrambled, miR-
30b/c and miR-21 for 48 h and then were treated with 50 or
100 ng/ml of superKiller TRAIL for 24 h. Cells were grown for 6 days
and then coloured with crystal violet-methanol solution
(Supplementary Figures 1A and B). The results indicated that
both miRs induced an increase of TRAIL resistance.
To further explore the role of miR-21 and -30b/c on TRAIL
sensitivity, we transfected U251 (Figure 3a) or LN229 (Figure 3b)
TRAIL-resistant cells with anti-miR-21, -30b, 30c, or with a
scrambled sequence. As shown in Figures 3a and b, transfection
of the anti-miR sequences was able to sensitize U251 and LN229
cells to TRAIL. Anti-miR-21 and -30c were also able to sensitize
to TRAIL the CALU-1-resistant non-small cell lung cancer (NSCLC)
TRAIL-resistant cell lines (Supplementary Figure 3C), indicating
that this effect was not restricted to glioma.
Identification of cellular targets of miR-30b/c and miR-21
in glioma cells
To identify cellular targets of miR-30b/c and -21, we used as first
attempt a bioinformatic search, using programs available on the
web including Pictar, TargetScan, miRanda and Microcosm target.
miR-21 targets different tumor suppressor genes and proteins
potentially involved in TRAIL resistance in glioblastoma
cells, such as PTEN (phosphatase and tensin homologue),
PDCD4 (programmed cell death 4), TPM1 (Tropomyosin 1) and
p53.15–17 Computer-assisted analysis identified the presence of
evolutionary-conserved binding sites for miR-21 in TAp63 gene.
We focused our attention on this p53 family member, as it
regulates the expression of TRAIL receptors and molecules
involved in TRAIL signaling.18 We also searched for miR-30
targets and among them we focused on caspase-3.
TRAIL-resistant and TRAIL-sensitive glioma or NSCLC cells
exhibited different levels of miR-21 and -30c assessed by either
qRT–PCR (Figure 4a and Supplementary Figure 3A) or by northern
blot analysis (Supplementary Figure 4). Interestingly, we observed
a reduction of protein (Figure 4b and Supplementary Figure 3D)
and mRNA (Figure 4c) levels of TAp63 and caspase-3 upon,
respectively, miR-21 or miR-30c and miR-30b (data not shown)
transfection in TRAIL-sensitive cell lines. We didn’t observe aCe
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Figure 1. TRAIL sensitivity of glioblastoma cells. Glioblastoma cell
lines (104 cell) were treated with superKiller TRAIL. After 24 h of
treatment, the effect on cell death was assessed with MTT assay
(a) or by propidium iodide staining and FACS analysis (b).
Table 1. microRNA identified in TRAIL-resistant glioma (LN229 and
TB10) compared with TRAIL-sensitive (T98G, LN18) cells
miR P-value Fold difference
hsa-miR-125b1-A 6.09e! 05 3.033
hsa-miR-30b-A 9.14e! 05 2.041
hsa-miR-30c-A 0.0001199 2.337
hsa-miR-146b-A 0.0001556 5.972
hsa-miR-181a-5p-A 0.0004698 2.66
hsa-miR-181d-A 0.0004817 3.035
hsa-miR-21-A 0.0032482 1.949
miRNA expression profiles in TRAIL-sensitive vs TRAIL-resistant cells.
miRNA screening was performed in triplicate for TRAIL-sensitive and
TRAIL-resistant cell lines by a microarray as described in Materials and
methods. A two-tailed, two-sample t-test was used (Po0.05). Seven
miRNAs were found to be significantly deregulated in TRAIL-resistant cells
compared with the TRAIL sensitive.
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decrease in the levels of other caspases upon miR-30c transfection
(Figure 4b). On the contrary, TAp63 and caspase-3 protein levels
increased upon anti-miR-21 and anti-miR-30c transfection
(Figure 3c and Supplementary Figure 3D) in TRAIL-resistant cell
lines. To verify a direct link between the miR-21/TAp63 and miR-
30b/c and caspase-3, we performed luciferase assay by co-
transfecting pGL3-30 untranslated region (UTR) vectors along with
miR-21 or miR-30c. The results obtained indicated a direct
interaction of miR-21 with TAp63 and miR-30c with caspase-3
(Figure 4d). As indicated in Figure 4d, miR-30b and -30c have the
same seed sequence that recognizes caspase-3, differing only at
the latest four nucleotides of the 50. Therefore, miR-30b down-
regulates caspase-3 at the same extent than miR-30c (data not
shown). Deletions in seed complementary sites rescued the
repression of miR-21 and miR-30c on their identified targets
(Figure 4d).
Validation of miR-21 and miR-30b/c mechanisms of action
To demonstrate that miR-21 and miR-30b/c, by downregulating
TAp63 and caspase-3, are responsible for the TRAIL resistance
observed in T98G and LN18 cells, we transfected T98G with
caspase-3 or TAp63 complementary DNAs lacking the miRNA-
binding site in their 30UTR or with a control vector and miR-30c
(Figure 5a) or miR-21 (Figure 5b). Interestingly, transfection of
TAp63 and caspase-3 was able to overcome the effects of miR-21
and miR-30c, decreasing cell viability and increasing apoptosis
(Figures 5a and b). The data were confirmed by colony assay in
T98G cells (Supplementary Figures 2A and B). Similar results were
obtained when we analyzed miR-30b (data not shown). These
rescue experiments proved the causative link between miR-21/
TAp63 and caspase-3/miR-30b/c and TRAIL sensitivity.
Effect of miR-21 and miR-30c expression on TRAIL sensitivity in
primary human glioma cell lines
MiR-21 and miR-30c expression levels were measured by qRT–PCR
in nine different human primary cell lines (Figure 6a), eight
derived from glioblastoma tumors (patient no. 1 to no. 8) and one
from tissue surrounding the tumor (patient no. 9), and compared
with TRAIL sensitivity. As shown in Figure 6b, TRAIL sensitivity
correlated with miR-21 and miR-30c expression levels in all cases
analyzed, with the exception of control sample that did not
respond to TRAIL. Moreover, anti-miRs expression in TRAIL-
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resistant primary cultured cells (patient no. 1 and no. 2) was able
to determine an increase of TRAIL sensitivity (Figure 6c) and
concomitantly an increase of the levels of TAp63 and caspase-3
(Figure 6d).
DISCUSSION
Sensitization of cancer cells to apoptosis could be a valuable
strategy to define new treatment options for cancer, in particular
when using agents that aim to directly activate apoptotic
pathways. A promising agent is the death receptor ligand TRAIL,19
as it induces apoptosis in most cancer cells, but not in normal
cells.20,21 Moreover, TRAIL exhibits potent tumoricidal activity
in vivo in several xenograft models, including malignant
glioma.22,23 Indeed, agonistic anti-TRAIL receptor monoclonal
antibodies (mAbs), including mapatumumab (HGS-ETR1, anti-
human DR4 mAb),24 lexatumumab (HGS-ETR2, anti-human DR5
mAb)25 and MD5-1 (anti-mouse DR5 mAb) are currently under
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intensive investigation. The former two mAbs have been tested in
phase 1 clinical trials in patients with systemic malignancy,
exhibiting excellent safety profiles. Anti-mouse DR5 mAb MD5-1
could also be administered safely without inducing hepatotoxicity
either alone or in combination with histone deacetylase inhibitors
in mice.26 The induction of apoptosis by TRAIL is essentially
dependent on the expression of specific TRAIL receptors and on
the activation of caspases,20 thus the regulation of the expression
levels of those molecules is of fundamental importance.
MicroRNAs are emerging as key regulators of multiple pathways
involved in cancer development and progression,27–29 and may
become the next targeted therapy in glioma. The present study
shows that microRNA expression may modulate TRAIL-induced
apoptosis in glioma cells, by the regulation of caspase-3 and
TAp63 levels. We analyzed the miRs profile of TRAIL-resistant
compared with TRAIL-sensitive glioma cells. We then focused our
attention on miR-30b/c and miR-21, as only these miRs among
those identified by the array, demonstrated the ability to revert
the TRAIL-sensitive phenotype. We also provided evidences that
this regulation is not restricted to glioma, but it is present also in a
different type of cancer such as NSCLC.
MiR-21 has been found overexpressed in high-grade glioma
patients30 and studies have identified different miR-21 key targets
for glioma biology, such as RECK, TIMP3, Spry2 and Pdcd4 genes,
which are suppressors of malignancy and inhibitors of matrix
metalloproteinase.16,31–33 Moreover, levels of expression of miR-21
have been associated to patients survival.34
Other studies indicate that knockdown of miR-21 in cultured
glioblastoma cells triggers activation of caspases and leads to
increased apoptotic cell death.35 Corsten et al.36 hypothesized that
suppression of miR-21 might sensitize gliomas for cytotoxic tumor
therapy. With the use of locked nucleic acid (LNA)-anti-miR-21
oligonucleotides and neural precursor cells (NPC) expressing a
secretable variant of TRAIL (S-TRAIL), they showed that the
combined suppression of miR-21 and NPC-S-TRAIL leads to a
synergistic increase in caspase activity and a decreased cell
viability in human glioma cells in vitro and in vivo in xenograft
experiments. Interestingly, Papagiannakopoulos et al.15 described
that miR-21 targets multiple important components of the p53
tumor-suppressive pathways. They showed that downregulation
of miR-21 in glioblastoma cells leads to repression of growth,
increased apoptosis and cell cycle arrest, through the regulation of
target proteins such as HNRPK and TAp63. Our study describes for
the first time the direct link between miR-21, TAp63 and TRAIL
sensitivity. We demonstrated that miR-21 targets the 30UTR
sequence of TAp63, and that transfection of miR-21 is able to
downregulate TAp63 at both mRNA and protein levels. More
importantly, we demonstrated that miR-21, through TAp63, is able
to modulate TRAIL sensitivity, as the co-transfection of miR-21 and
TAp63 cDNA renders the cells again responsive to TRAIL. TAp63 is
a transcription factor that regulates the expression levels of
different apoptosis-regulating genes, such as TRAIL receptors,
bcl2l11 and Apaf1.18 Thus, it is possible that those apoptosis-
regulating molecules are regulated by miR-21 through TAp63.
Several studies link miR-30 to apoptosis and human cancer.
Li et al.37 demonstrated that miR-30 family members inhibited
mitochondrial fission through the suppression of the expression
of p53 and its downstream target Drp1, whereas, Joglekar et al.38
demonstrated that miR-30 may have a role in epithelial-to-
mesenchymal transition. Our recent data demonstrate that miR-
30 targets the anti-apoptotic protein BIM, participating to
gefitinib resistance in lung cancer.39 MiR-30 has been also
associated with stem cell properties. Yu et al.40 described that
miR-30 is reduced in breast tumor stem cells (BT-ICs), and
demonstrated that enforced expression of miR-30 in BT-ICs
inhibits their self-renewal capacity by reducing Ubc9,
and induces apoptosis through silencing ITGB3. In our hands,
miR-30 overexpression inhibits TRAIL-induced apoptosis in
glioma cells by targeting caspase-3. In fact, modulating the
expression of either miR-30 or caspase-3, we observed a
modification of TRAIL sensitivity of glioma cells. The opposing
results on the role of miR-30 on cell death may be ascribed either
to different cell system (breast vs glioma), or to different type of
cancer cell (stem vs differentiated cells). In favour of this
hypothesis, many reports describe opposing role of miRs in a
different cell contest.28 Recently, miR-30d has been described to
target caspase-3 in breast cancer cells, and thus to regulate
apoptosis.41 The seed sequence recognizing the 30UTR of
caspase-3 is highly homologous within the members of the
miR-30 family (miR-30b/c/d) suggesting a more generalized role
of miR-30 family members in the regulation of cell death and
cancer progression.
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In many experiments, we observed that there is a redundancy
within miR-21 and miR-30 in the regulation of TRAIL sensitivity.
Our data, either in primary or in established cell lines,
demonstrates that it is sufficient that one of the two miRs is
highly expressed in the cells, that apoptosis resistance will
manifest. We have also observed that miR-30 has a predominant
effect in contrasting TRAIL-induced apoptosis. This may be related
to the effect of this miR in targeting one important component of
the cell death machinery, that is, caspase-3.
In conclusion, our study analyzed microRNA expression pattern
in TRAIL-resistant and TRAIL-sensitive glioma cells, and identified
specific miRs and their targets involved in the regulation of the
apoptotic programme. This may be of relevance for future cancer
therapy improvement in glioma.
MATERIALS AND METHODS
Cell culture and transfection
U87MG, T98G, U251, TB10, CALU-1 and 293 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM). H460 were grown in RPMI. Media were
supplemented with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine and 100U/ml penicillin/streptomycin. LN229 and LN18 were
grown in Advanced DMEM (Invitrogen, Milan Italy)þ 2mM Glutamineþ 5%
fetal bovine serum. For miRs transient transfection, cells at 50% confluency
were transfected using Oligofectamine (Invitrogen) with 100 nM of pre-miR-
30c, -30b, -125b, -146b, -181a, -21, miR-scrambled or anti-miR- (Applied
Biosystems, Milan, Italy). For caspase-3 and TAp63 transient transfection,
cells were transfected using Lipofectamine and Plus Reagent with 4 mg of
caspase-3 cDNA (Origene, Rockville, MD, USA) or TAp63 cDNA for 24 h.
TAp63 cDNA was obtained from Professor Viola Calabro` (Naples).
SuperKiller TRAIL for cell treatment was purchased from Enzo Biochem
(New York, NY, USA).
Primary cell cultures
Glioblastoma specimens were collected at neurosurgical Unit of Cardarelli
hospital (Naples). All the samples were collected according to a prior
consent of the donor before the collection, acquisition or use of human
tissue. To obtain the cells, samples were mechanically disaggregated, then
the lysates were grown in DMEM-F12 medium supplemented with 10%
fetal bovine serum 1% penicillin streptomicyn and 20 ng/ml EGF (Sigma-
Aldrich, Milan, Italy). To exclude a fibroblast contamination, cells were
stained for GFAP, a protein found in glial cells.
Protein isolation and western blotting
Cells were washed twice in ice-cold phosphate-buffered saline, and lysed
in JS buffer (50mM HEPES pH 7.5 containing 150mM NaCl, 1% Glycerol, 1%
Triton X-100, 1.5mM MgCl2, 5mM EGTA, 1mM Na3VO4 and 1# protease
inhibitor cocktail). Protein concentration was determined by the Bradford
assay (Bio-Rad, Milan, Italy) using bovine serum albumin as the standard,
and equal amounts of proteins were analyzed by SDS–PAGE (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose membranes
(Millipore, Bedford, MA, USA). For immunoblot experiments, membranes
were blocked for 1 h with 5% non-fat dry milk in Tris-buffered saline
containing 0.1% Tween-20, and incubated at 4 1C over night with primary
antibody. Detection was performed by peroxidase-conjugated secondary
antibodies using the enhanced chemiluminescence system (GE Healthcare,
Milan, Italy). Primary antibodies used were: anti-bActin from Sigma-Alrich;
anti-caspase-8, 9 and 10 were from Cell Signalling Technology (Boston, MA,
USA); anti-Caspase 3 and anti-TAp63 from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA).
miRNA microarray experiments
From each sample, 5 mg of total RNA (from T98G, LN18, TB10, LN229 cells)
was reverse transcribed using biotin-end-labelled random-octamer oligo-
nucleotide primer. Hybridization of biotin-labelled cDNA was performed on
an Ohio State University custom miRNA microarray chip (OSU_CCC version
3.0), which contains 1150 miRNA probes, including 326 human and 249
mouse miRNA genes, spotted in duplicates. The hybridized chips were
washed and processed to detect biotin-containing transcripts by
streptavidin-Alexa647 conjugate and scanned on an Axon 4000B micro-
array scanner (Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analyzed with GENESPRING 7,2 software
(zcomSilicon Genetics, Redwood City, CA, USA). Expression data were
median-centered by using both the GENESPRING normalization option
and the global median normalization of the BIOCONDUCTOR package
(www.bioconductor.org) with similar results. Statistical comparisons were
done by using the GENESPRING ANOVA tool, predictive analysis of
microarray and the significance analysis of microarray software (http://
www-stat.stanford.edu/Btibs/SAM/index.html).
RNA extraction and real-time PCR
Total RNAs (miRNA and mRNA) were extracted using Trizol (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription of total
miRNA was performed starting from equal amounts of total RNA per
sample (1mg) using miScript reverse Transcription Kit (Qiagen, Milan, Italy),
for mRNASuperScript III Reverse Transcriptase (Invitrogen) was used. For
cultured cells, quantitative analysis of Caspase-3, Tap63, b-Actin (as an
internal reference), miR-30b/c, miR-21 and RNU5A (as an internal
reference) were performed by real-time PCR using specific primers
(Qiagen), miScript SYBR Green PCR Kit (Qiagen) and iQ SYBR Green
Supermix (Bio-Rad), respectively. The reaction for detection of mRNAs was
performed as follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 60 1C for 300
and 72 1C for 300 . The reaction for detection of miRNAs was performed as
follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 55 1C for 300 and 70 1C for
300 . All reactions were run in triplicate. The threshold cycle (CT) is defined
as the fractional cycle number at which the fluorescence passes the
fixed threshold. For relative quantization, the 2(!DCT) method was used
as previously described.42 Experiments were carried out in triplicate
for each data point, and data analysis was performed by using software
(Bio-Rad).
Northern blot analysis
RNA samples (30mg) were separated by electrophoresis on 15%
acrylamide, 7mol/l urea gels (Bio-Rad, Hercules, CA, USA) and transferred
onto Hybond-Nþ membrane (Amersham Biosciences, Piscataway, NJ,
USA). Hybridization was performed at 37 1C in 7% SDS/0.2 mol/l Na2PO4
(pH 7.0) for 16 h. Membranes were washed at 42 1C, twice with 2#
standard saline phosphate (0.18mol/l NaCl/10mmol/l phosphate (pH 7.4)),
1 mmol/l EDTA (saline–sodium phosphate–EDTA; SSPE) and 0.1% SDS and
twice with 0.5# SSPE/0.1% SDS. The oligonucleotides (PRIMM, Milan, Italy)
used, complementary to the sequences of the mature miRNAs, were: miR-
21-probe 50-TCAACATCAGTCTGATAAGCTA-30 ; miR-30c-probe 50-GCTGAG
AGTGTAGGATGTTTACA-30 . An oligonucleotide complementary to the
U6 RNA (50-GCAGGGGCCATGCTAATCTTCTCTGTATCG-30) was used to
normalize the expression levels. Totally, 100 pmol of each probe were
end labelled with 50mCi [g-32P]ATP using the poly-nucleotide kinase
(Roche, Basel, Switzerland). Blots were stripped by boiling in 0.1% SDS for
10min before re-hybridization.
Luciferase assay
The 30 UTR of the human Caspase-3 genes was PCR amplified using the
following primers: Caspase-3 forward: 50-TCTAGAAGGGCGCCATCGCCAAG
TAAGAAA-30 , Caspase-3 reverse: 50-TCTAGACCCGTGAAATGTCATACTGA
CAG-30 and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega, Milan, Italy). A deletion was introduced into
the miRNA-binding sites by using the QuikChange Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) using the following: primers: Caspase-3
mut forward 50-GCAAAATTCTTAAGTATGTTATTTTCTGTTGAAATCAAAGGA
AAATAGTAATGTTTTATACT-30 . Caspase-3mut reverse 50-AGTATAAAACAT
TACTATTTTCCTTTGATTTCAACAGAAAATAACATACTTAAGAATTTTGC-30 .
The 30 UTR of the human TAp63 gene was PCR amplified using the
following primers: TAp63 forward: 50-TCTAGAGCAAGAGATAAGTCTTT
CATGGCTGCTG-30 , TAp63 reverse: 50-TCTAGATGGAAATCCCACTATCCCA
AG-30 , and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega). A deletion was introduced into the miRNA-
binding sites by using the QuikChange Mutagenesis Kit (Stratagene) using
the following: primers:TAp63 mut forward 50-CTGGTCAAGGGCTGTCATTG
CACTCCATTTTAATTT-30 TAp63 mut reverse 50-AAATTAAAATGGAGTGCAAT
GACAGCCCTTGACCAG-30 .
Hek-293 cells were cotransfected with 1.2mg of generated plasmid and
400mg of a Renilla luciferase expression construct pRL-TK (Promega) with
Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h post transfec-
tion and assayed with Dual Luciferase Assay (Promega) according to the
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manufacturer’s instructions. Three independent experiments were per-
formed in triplicate.
Cell death quantification
Cells were plated in 96-well plates in triplicate, stimulated and incubated
at 37 1C in a 5% CO2 incubator. SuperKiller TRAIL was used at final
concentration of 50 or 100 ng/ml for 24 h. Apoptosis was analyzed via
propidium iodide incorporation in permeabilized cells by flow cytometry.
The cells (2# 105) were washed in phosphate-buffered saline and
resuspended in 200ml of a solution containing 0.1% sodium citrate, 0.1%
Triton X-100 and 50 mg/ml propidium iodide (Sigma). Following incubation
at 4 1C for 30min in the dark, nuclei were analyzed with a Becton Dickinson
FACScan flow cytometer (Becton Dickinson, Milan, Italy). Cellular debris
was excluded from analyses by raising the forward scatter threshold, and
the DNA content of the nuclei was registered on a logarithmic scale. The
percentage of elements in the hypodiploid region was calculated. Cell
viability was evaluated with the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s protocol.
Metabolically active cells were detected by adding 20ml of MTS to each
well. After 2 h of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy).
Colony assay
Cells were transfected with miR-scrambled, miR-30b/c or miR-21 for 24 h,
then were harvested and 2.4# 104 cells were plated in six-well plates. After
24 h, cells were treated with 50 or 100 ng/ml of superKiller TRAIL for 24 h,
as indicated. Cells were transferred to 100mm dishes and let grown for
6 days. Finally, the cells were coloured with 0.1% crystal violet dissolved in
25% methanol for 20min at 4 1C. Dishes were washed with water and then
let dry on the bench, and then photographs were taken.
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Abstract
Glioblastoma multiforme (GBM) is one of the most deadly types of cancer. To date, the best clinical approach for
treatment is based on administration of temozolomide (TMZ) in combination with radiotherapy. Much evidence
suggests that the intracellular level of the alkylating enzyme O6-methylguanine–DNA methyltransferase (MGMT)
impacts response to TMZ in GBM patients. MGMT expression is regulated by the methylation of its promoter.
However, evidence indicates that this is not the only regulatory mechanism present. Here, we describe a hitherto
unknown microRNA-mediated mechanism of MGMT expression regulation. We show that miR-221 and miR-222 are
upregulated in GMB patients and that these paralogues target MGMT mRNA, inducing greater TMZ-mediated cell
death. However, miR-221/miR-222 also increase DNA damage and, thus, chromosomal rearrangements. Indeed,
miR-221 overexpression in glioma cells led to an increase in markers of DNA damage, an effect rescued by re-
expression of MGMT. Thus, chronic miR-221/222-mediated MGMT downregulation may render cells unable to repair
genetic damage. This, associated also to miR-221/222 oncogenic potential, may poor GBM prognosis.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
deadly primary tumor of the central nervous system. Despite
several therapeutic advances, the prognosis for GBM remains
poor, with a median survival lower than 15 months [1,2].
Currently, first-line therapy for GBM comprises surgery with the
maximum feasible resection, followed by a combination of
radiotherapy and treatment with the alkylating agent
temozolomide (TMZ), also referred to by its brand name
Temodal [3,4,5]. TMZ is a methylating agent that modifies DNA
in several positions, one of them being O6-methylguanine MeG
(O6MeG) [6]. If the methyl group is not removed before cell
division, this modified guanine preferentially pairs with thymine
during DNA replication, triggering the DNA mismatch repair
(MMR) pathway, DNA double-strand breaks, and, therefore,
the apoptotic pathway [7,8]. O6-methylguanine–
methyltrasferase (MGMT) is a suicide cellular DNA repair
enzyme ubiquitously expressed in normal human tissues.
MGMT does not act as a part of a repair complex but works
alone [9]. To neutralize the cytotoxic effects of alkylating
agents, such as TMZ, it rapidly reverses alkylation at the O6
position of guanine, transferring the alkyl group to an internal
cysteine residue in its active site. In this form, the enzyme is
inactive and, thus, requires de novo protein synthesis. In
tumors, high levels of MGMT activity are associated with
resistance to alkylating agents [10]. In contrast, epigenetic
silencing of MGMT gene expression by promoter methylation
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results in sensitization to therapy [11,12]. However, some
studies have reported that MGMT promoter methylation does
not always correlate with MGMT expression and with response
to therapy [13,14]. Therefore, the existence of other
mechanisms of MGMT regulation should be postulated.
MicroRNAs (miRs) are small regulatory molecules that have
a role in cancer progression and in tumor therapy response
[15,16]. By negatively regulating the expression of their targets,
miRs can act as tumor suppressors or oncogenes [17]. miRs
may also regulate DNA damage response and DNA repair,
interfering with the response to chemotherapy or radiotherapy
[18]. Several studies have indicated that the modulation of miR
expression levels is a possible therapeutic strategy for cancer.
The paralogues miR-221 and miR-222 have frequently been
found to be dysregulated in glioblastoma and astrocytomas
[19,20,21,22]. Their upregulation increases glioma cell
proliferation, motility, and in vivo growth in mouse models.
miR-221/222 have also been shown to be implicated in cellular
sensitivity to tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-treatment [23,24,25]. In this manuscript, we
provide evidence that miR-221 and miR-222 regulate MGMT
expression levels in glioblastoma, increasing the response to
TMZ, but due to their oncogenic potential, affect overall patient
survival negatively.
Materials and Methods
Cell culture and transfection
U87MG, T98G, LN428, LN308, A172, and HEK-293 cells
were grown in DMEM. LN229 were grown in Advanced DMEM
(Gibco, Life technologies, Milan, Italy). T98G, U87MG, and
LN229 were from ATCC (LG Standards, Milan Italy); LN428,
LN308, and A172 were kindly donated by Frank Furnari (La
Jolla University). Media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) -5% FBS for LN229 -2
mM L-glutamine, and 100 U/ml penicillin/streptomycin. All
media and supplements were from Sigma Aldrich (Milan, Italy).
For overexpression of miRs, cells at 50% confluency were
transfected using Oligofectamine (Invitrogen, Milan, Italy) and
100nM pre-miR-221 or pre-miR-222, a scrambled miR or anti-
miR-221/222 (Applied Biosystems, Milan, Italy). For
overexpression of MGMT, cells were transfected using
Lipofectamine and Plus Reagent with 4 µg of MGMT cDNA
(Origene, Rockville MD USA). Temozolomide was purchased
from Sigma Aldrich (Milan, Italy).
Human Glioma samples
A total of 34 formalin-fixed, paraffin-embedded (FFPE) tissue
samples were collected from the archives of the Department of
Pathology, University Hospital of Kuopio, Finland. Permission
to use the material was obtained from the National Supervisory
Authority for Welfare and Health of Finland, and the study was
accepted by the ethical committee of the Northern Savo
Hospital District, Kuopio, Finland.
Primary cell cultures
Glioblastoma specimens were obtained as previously
described [19]. Samples were mechanically disaggregated, and
the lysates grown in DMEM-F12 medium supplemented with
10% FBS, 1% penicillin streptomycin, and 20 ng/ml epidermal
growth factor (EGF; Sigma-Aldrich, Milan, Italy). To determine
the glial origin of the isolated cells, we stained the cultures for
glial fibrillary acidic protein (GFAP), a protein found in glial
cells.
Protein isolation and Western blotting
Cells were washed twice in ice-cold PBS and lysed in JS
buffer (50 mM HEPES pH 7.5 containing 150 mM NaCl, 1%
Glycerol, 1% Triton X100, 1.5mM MgCl2, 5mM EGTA, 1 mM Na
3VO4, and 1X protease inhibitor cocktail). Protein concentration
was determined by the Bradford assay (BioRad, Milan, Italy)
using bovine serum albumin (BSA) as the standard, and equal
amounts of proteins were analyzed by SDS-PAGE (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose
membranes (GE Healthcare, Milan, Italy). For immunoblot
experiments, membranes were blocked for 1 hr with 5% non-fat
dry milk in Tris-buffered saline (TBS) containing 0.1%
Tween-20, and incubated at 4°C overnight with primary
antibody. Detection was performed by peroxidase-conjugated
secondary antibodies using the enhanced chemiluminescence
system (GE Healthcare, Milan, Italy). Primary antibodies used
were: anti-β-actin from Sigma-Aldrich (Milan Italy); anti-
caspase-3 and anti-PARP from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA), anti-γH2AX from Millipore (Milan,
Italy), anti-p53, pser15 p53, and phosphorylated-ATM from Cell
Signaling Technology (Milan, Italy).
RNA extraction and Real-Time PCR
Cell culture: Total RNA (microRNA and mRNA) were
extracted using Trizol (Invitrogen, Milan, Italy) according to the
manufacturer’s protocol.
Tissue specimens
Total RNA (miRNA and mRNA) from FFPE tissue specimens
was extracted using RecoverAll Total Nucleic Acid isolation Kit
(Ambion, Life Technologies, Milan, Italy) according to the
manufacturer’s protocol. Reverse transcription of total miRNA
was performed starting from equal amounts of total RNA/
sample (1µg) using miScript reverse Transcription Kit (Qiagen,
Milan, Italy), and with SuperScript® III Reverse Transcriptase
(Invitrogen, Milan, Italy) for mRNA. Quantitative analysis of
MGMT, β-actin (as an internal reference), miR-221, miR-222,
and RNU5A (as an internal reference) were performed by
RealTime PCR using specific primers (Qiagen, Milan, Italy),
miScript SYBR Green PCR Kit (Qiagen, Milan, Italy), and iQTM
SYBR Green Supermix (Bio-Rad, Milan, Italy), respectively.
The reaction for detection of mRNAs was performed as follows:
95°C for 15’, 40 cycles of 94°C for 15″, 60°C for 30″, and 72°C
for 30″. The reaction for detection of miRNAs was performed as
follows: 95°C for 15’, 40 cycles of 94°C for 15″, 55°C for 30″,
and 70°C for 30″. All reactions were run in triplicate. The
threshold cycle (CT) is defined as the fractional cycle number
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at which the fluorescence passes the fixed threshold. For
relative quantization, the 2(-∆CT) method was used as previously
described [26]. Experiments were carried out in triplicate for
each data point, and data analysis was performed by using a
Bio-Rad software (Bio-Rad, Milan, Italy).
Luciferase assay
The 3’ UTR of the human MGMT gene was PCR amplified
using the following primers: MGMT-Fw:
5’TCTAGAGTATGTGCAGTAGGATGGATG3’; MGMT-Rv: 5’
TCCAGAGCTACAGGTTTCCCTTCC3’, and cloned
downstream of the Renilla luciferase stop codon in pGL3
control vector (Promega, Milan, Italy). A deletion was
introduced into the miRNA-binding sites with the QuikChange
Mutagenesis Kit (Stratagene, La Jolla CA USA) using the
following primers: MGMT-mut Fw: 5’
CTATATCCAAAAGGGAAACCTGTAGCTCTTGC 3’. MGMT-
mut Rw: 5’- GCAGAGCTACACGTTTCCCTTTTGGATATAG 3’.
HEK-293 cells were co-transfected with 1.2µg of plasmid and
400 µg of a Renilla luciferase expression construct, pRL-TK
(Promega, Milan, Italy), with Lipofectamine 2000 (Invitrogen,
Milan, Italy). Cells were harvested 24 hrs post-transfection and
assayed with Dual Luciferase Assay (Promega, Milan, Italy)
according to the manufacturer’s instructions. Three
independent experiments were performed in triplicate.
Cell death quantification
Cell viability was evaluated with the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Milan, Italy)
according to the manufacturer’s protocol. Metabolically active
cells were detected by adding 20 µL of MTS to each well. After
2 hrs of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy). For caspase-3 inhibition
experiments, ZVAD-Fmk was purchase from Calbiochem.
Comet assay
Alkaline comet assay was performed accordingly to
manufacturer’s instructions (Trevigen, Gaithersburg, Maryland,
USA). Briefly, 12x104 glioblastoma cell lines were transfected
with miRs or MGMT cDNA and then treated with TMZ in 6-well
plates. Cells were collected and then combined with
LMAgarose. The mixture was applied to Comet slides and kept
at 4°C in the dark for 10’. The slides were immersed in pre-
chilled lysis buffer for 30 min. The slides were washed and then
electrophoresis was carried out. The slides were fixed in 70%
ethanol for 5 min and let dry overnight. SYBR green was added
and comets were photographed at 100 x microscopes (Carl
Zeiss Inc., NY, USA).
γH2AX flow cytometric analysis
Treated cells were fixed with 2% paraformaldehyde for 1 hr.
Fixed cells were permeabilized with 0.1% Triton-X100/PBS for
5 min on ice. Blocking was done in PBS+2% BSA. Anti-
phosphorylated H2Ax antibody(Ser139, γH2Ax, Millipore,
Milan, Italy) was diluted in PBS and then FITC-conjugated goat
anti-mouse antibody (Santa cruz Biotechnology, CA, USA) was
used. Cells were analyzed with a Becton Dickinson FACScan
flow cytometer.
Caspase Assay
The assay was performed using the Colorimetric CaspACETM
Assay System, (Promega, Milan, Italy) as reported in the
instruction manual. Briefly, T98G cells were transfected with
miR-221 and/or MGMT cDNA, plated in 96-well plates, and
then treated with 300 µMol of temozolomide or with 10 µMol of
ZVAD-Fmk. After treatments, 100 µl caspase-3/-7 reagent was
added to each well for 1 hr in the dark. The plates were
analyzed in a Multilabel Counter (BioTek, Milan, Italy).
MGMT Methylation Analysis
DNA methylation status in the CpG island of MGMT was
established by PCR analysis of bisulfite modified genomic
DNA, which induces chemical conversion of unmethylated, but
not methylated, cytosine to uracil. DNA was extracted from cell
lines using the DNeasy blood and tissue kit (Qiagen, Milan,
Italy). DNA (1 µg) was modified with sodium bisulfite using the
EZ DNA methylation-gold kit (Zymo Research, CA, USA)
according to the manufacturer’s instructions. Methylation-
specific polymerase chain reaction (MSP) was performed with
primers specific for either methylated or the modified
unmethylated DNA. Primer sequences for the unmethylated
reaction were 5'TTTGTGTTTTGATGTTTGTAGGTTTTTGT3'
(forward primer) and
5'AACTCCACACTCTTCCAAAAACAAAACA3' (reverse
primer), and for the methylated reaction they were
5'TTTCGACGTTCGTAGGTTTTCGC3' (forward primer) and
5'GCACTCTTCCGAAAACGAAACG3' (reverse primer.) The
annealing temperature was 59°C. The cell line SW48 and in
vitro methylated DNA (CpGenome Universal Methylated DNA,
Millipore) were used as a positive control for the methylation of
MGMT and DNA from normal lymphocytes used as a negative
control. Controls without DNA were used for each set of
methylation-specific PCR assays. The methylation-specific
PCR product was loaded directly onto 2% agarose gels,
stained with syber safe, and examined under ultraviolet
illumination.
Colony Assay
Cells were transfected with scrambled miR or miR-221 for 24
hrs, harvested, and 2.4 x104 cells plated in 6-well plates. After
24 hrs, cells were treated with 300 µMol TMZ for 24 hrs, as
indicated. Cells were transferred to 100-mm dishes and grown
for 6 days. Finally, the cells were colored with 0.1% crystal
violet dissolved in 25% methanol for 20 min at 4°C. Dishes
were washed with water, left to dry on the bench, and then
photographs taken.
Statistical analysis
Student’s t test and nonparametric Mann-Whitney tests were
used to determine differences between values for normally
and, respectively, not normally distributed variables. A
probability level <0.05 was considered significant throughout
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the analysis. Data were analyzed with GraphPad Prism (San
Diego, CA, USA) for Windows.
Results
Sensitivity of human glioma cell lines to temozolomide
We analyzed the sensitivity to TMZ of human glioma cell
lines by exposing the cells to 300 µMol TMZ for 48 hours and
then assessing cell viability with the MTT assay (Figure 1A).
We observed different TMZ sensitivities, which correlated with
MGMT levels analyzed by Western blot (Figure 1B). We also
observed an inverse correlation between the level of MGMT
(Figure 1B) and miR-221 expression in glioma cell lines (Figure
1C). An RNA hybrid alignment bioinformatics search identified
a possible binding site for miR-221/222 at position 970 of the 3’
UTR of MGMT.
To examine whether miR-221/222 interfered with MGMT
expression by directly targeting the predicted 3’ UTR region,
we cloned this region downstream of a luciferase reporter gene
in the pGL3 vector. HEK-293 cells were co-transfected with the
reporter plasmid plus the negative control miR (scrambled
miR), miR-221, or miR-222. Only transfection of either miR-221
or miR-222 with the wild-type MGMT-3’UTR reporter plasmid
led to a significant decrease of luciferase activity. On the
Figure 1.  TMZ sensitivity and MGMT and miR-221/222
expression in glioma cells.  (A) Glioma cells were treated
with TMZ (300µMol) for 24 hr. Cell viability was evaluated with
an MTT assay. (B) Western blot analysis of MGMT expression
in glioblastoma cells. (C) Real time PCR of miR-221 expression
in glioblastoma cells. (D) RNA Hybrid prediction analyzes of
miR-222, miR-221, and MGMT 3’ UTR. In bold are shown the
mutated oligonucleotides. Luciferase activity of HEK-293 cells
transiently co-transfected with the luciferase reporter containing
wild-type MGMT-3’UTR or mutant MGMT-3’UTR in the
presence of pre-miR-222, miR-221, or scrambled
oligonucleotide. Representative of at least three independent
experiments. *** p<0.001 versus control, ** p<0,0037 versus
control.
doi: 10.1371/journal.pone.0074466.g001
contrary, co-expression of the scrambled miR had no effect
(Figure 1D). In addition, miR-221/222’s effect on the promoter
of MGMT was reduced with the mutant MGMT-3’UTR reporter,
in which the seed sequence was mutated. Together, these
results demonstrate that miR-221/222 directly target
MGMT-3’UTR, thereby reducing MGMT expression.
miR-221/222 target MGMT protein and mRNA
In order to establish a causal link between miR-221/222 and
MGMT expression, we transfected T98G cells with either pre-
miR-221 or pre-miR-222 for 72 hrs and then analyzed MGMT
levels by Western blot and real time-PCR. Upon miR
transfection, MGMT protein and mRNA were downregulated
(Figure 2A). In contrast, MGMT expression was increased
upon transfection with anti-miR-221 or -222 in U87MG cells
(Figure 2B). Similarly, miR-221/222, induced downregulation of
MGMT in LN428 cells, another TMZ-resistant glioma cell line
(Figure 2C), and in A375 cells, a TMZ-resistant melanoma cell
line (Figure 2D). Since MGMT expression is mainly dependent
on the methylation status of its promoter [27], we determined if
miR-221/222 acted by modulating MGMT promoter
methylation. To this end, we performed a bisulfite modification
assay by PCR using specific primers for both methylated and
unmethylated MGMT promoter. As shown in Figure 2E,
miR-221/222 expression in T98G cells, or anti-miR expression
in U87MG cells, did not modify the methylation profile of the
MGMT promoter.
miRs-221/222 modulate TMZ sensitivity in glioma cells
To verify if miR-221/222 play a role in the modulation of TMZ
sensitivity because of their effects on MGMT expression, we
characterized the viability of T98G, LN428, and A375 cells
transfected with miR-221/222 and then treated with TMZ for 24
hrs. As shown in Figure 3A, miR-221/222 transfection
increased the response to TMZ. These results were also
confirmed by proliferation and colony assays (Figure 3B and
3C). To establish a causal link between miR-221 expression
and MGMT downregulation, we performed a rescue experiment
with simultaneous overexpression of miR-221 and MGMT
cDNA in two different cell lines (T98G and LN428). As shown in
Figure 3D, the effect of miR-221 on TMZ response was
abolished by MGMT overexpression. We then verified in nine
different glioblastoma primary cell lines and in six glioma cell
lines any correlation between miR-221 expression and TMZ
sensitivity. As shown, TMZ sensitivity positively correlated with
the expression level of miR-221 (Figure 3E).
miR-221 promotes apoptotic cell death
In order to evaluate the mechanism of TMZ-induced cell
death, we assessed the presence of apoptotic cells by PI
staining and flow cytometry upon miR-221 transfection and
TMZ treatment. We found that TMZ increased apoptotic cell
death in miR-221-overexpressing cells compared with control
cells. Interestingly, this effect was rescued by the co-
expression of MGMT cDNA with miR-221 (Figure 4A).
Caspase-3/7 activation assay further confirmed the
involvement of the apoptotic machinery. As shown in Figure
4B, miR-221 expression increased caspase-3 activity upon
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TMZ treatment, while the co-expression of MGMT cDNA with
miR-221 abolished this effect. Simultaneous treatment with the
caspase inhibitor ZVAD-fmk and TMZ was able to decrease
caspase activity, confirming that TMZ induced cell death by a
caspase-mediated mechanism. Caspase-3 activation,
observed by Western blot in miR-221-transfected cells after 24
hrs of TMZ treatment, was rescued by MGMT cDNA (Figure
4C). Coherently, we observed an increase in cell viability after
miR-221 transfection and simultaneous treatment with TMZ
and ZVAD-fmk (Figure 4D).
miR-221 promotes DNA damage after TMZ treatment
MGMT activity repairs DNA by removing DNA adducts
caused by TMZ treatment. The absence of MGMT increases
cell death upon exposure to TMZ, but, as a long-term effect,
may increase DNA damage, and thus the accumulation of
mutations. We investigated whether miR-221 may increase
DNA damage upon TMZ treatment by down-modulating MGMT
expression. This was assessed by a comet assay, which
quantifies double-stranded DNA (dsDNA) breaks, in T98G cells
transfected with miR-221 or a scrambled sequence and then
treated with TMZ at different times. We found that miR-221
produced a significant enhancement of dsDNA breaks (Figure
5A). To strengthen our hypothesis, we looked for the
phosphorylation status of histone H2AX (γH2AX) at Ser139,
which reflects dsDNA break formation. As shown in Figure 5B,
Figure 2.  miR-221/222 target MGMT.  (A) Western blot
analysis and real time PCR of MGMT protein and RNA after
miR-221/222 transfection of T98G cells. (B) Western blot
analysis and real time PCR of MGMT protein and RNA after
anti-miR-221 and -222 transfection of U87MG cells. (C)
Western blot of MGMT expression upon miR-221 transfection
of LN428 cells. (D) Western blot analysis of MGMT expression
in T98G cells, as a control, and the melanoma cell line A375
upon miR-221 transfection. (E) Analysis of methylation status
of MGMT promoter in T98G and U87MG upon miR- or anti-
miR-221/222 transfection. U is for the un-methylated form, M
for methylated form, NL is for normal lymphocytes, used as
control.
doi: 10.1371/journal.pone.0074466.g002
miR-221 significantly increased γH2AX, as assessed by
immunocytofluorescence (upper panel) or by Western blot
(lower panel), suggesting that miR overexpression may induce
DNA damage. This effect was even stronger in the presence of
TMZ, but was rescued by MGMT cDNA (Figure 5B, middle
panel). Furthermore, we also observed an increase of other
DNA damage markers, such as P-ATM, P-p53ser15 and PARP
cleavage, upon miR-221 transfection; this was even stronger
upon treatment with both miR-221 and TMZ (Figure 5C). These
effects were rescued by the simultaneous expression of MGMT
with miR-221. Taken together, these data suggest that the
targeting of MGMT by miR-221 increases DNA damage. This
effect was amplified by TMZ treatment.
MGMT and miR-221 expression in glioblastoma
patients
We then evaluated the expression of MGMT and miR-221 in
human glioblastoma samples. Patients were clustered into two
separate groups: a long survival (survival >15 months) group
and a short survival (survival <15 months) group, according to
common classification [2].
We first analyzed the methylation profile of the MGMT
promoter, and then MGMT mRNA and miR-221 levels. We
performed methylation-specific PCR (MSP) on 33 human
Figure 3.  miR-221 modulates TMZ sensitivity.  (A) Cell
viability of T98G, LN428, and A375 cells transfected with
miR-221 and miR-222 upon TMZ treatment (300 µMol) for 24
hrs. **p value<0.0082 versus scr column, ***p value<0.005
versus scr column. (B) Growth curve of T98G and LN428 cells
transfected or not with miR-221 after 24 hrs of treatment with
TMZ. (C) Colony assay of T98G and LN428 cells transfected
with miR-221 and then treated for 24 hrs with TMZ (300 µMol).
Cells were left to grow for 6 days after treatment removal. (D)
MGMT expression rescues cell viability after TMZ treatment in
T98G and LN428 cells overexpressing miR-221 **p
value<0.0082 versus untransfected MGMT column. (E)
Correlation between miR-221 expression and TMZ sensitivity in
nine primary glioblastoma cell lines and in six glioblastoma cell
lines.
doi: 10.1371/journal.pone.0074466.g003
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glioblastoma paraffin-embedded tissues, and found 27 to be
unmethylated and 4 to be methylated (samples 2, 21, 22, and
28) (Figure S1). For two samples (#31 and #32), it was not
possible to define the MGMT promoter methylation profile. We
then analyzed the effect of miR-221 on MGMT regulation
among 15 unmethylated samples from which we obtained
sufficient RNA for real time PCR analysis. We identified 4 long-
(#1, #4, #10, and #14) and 11 short- (#6, #7, #8, #12, #13, #17,
#18, #23, #25, #32, and #33) survival patients. We found that
the short-survival group exhibited a higher miR-221 level and a
lower MGMT level compared with the long-survival group
(Figure 6 A,B). These data supports our in vitro evidence of an
inverse correlation between miR-221 and MGMT expression.
Furthermore, this observation identifies miR-221 as a negative
prognostic factor for survival.
Discussion
Much evidence suggests that the intracellular level of the
alkylating enzyme MGMT affects TMZ response in GBM
patients [10,11]. Low levels of MGMT are associated with a
better TMZ response, because in the absence of MGMT the
cells are not able to repair the TMZ-induced base mismatch.
Figure 4.  miR-221 promotes DNA damages upon TMZ
treatment.  (A) Apoptotic cell death assessed by FACS in
T98G cells transfected with miR-221 or scrambled sequence
and MGMT and treated with TMZ for 24 hrs. *** p value< 0.005
versus untrasfected MGMT column. (B) Active caspase-3
quantification in T98G cells as indicated and treated with TMZ
for 24 hrs in the presence or absence of 3 hrs pre-treatment
with ZVAD-fmk. (C) Upper panel Time course analysis of
caspase-3 activation upon TMZ treatment in T98G cells
transfected with miR-221 or with scrambled sequence. Lower
panel Western blot analysis of caspase-3 activation after
miR-221 and MGMT transfection. (D) Cell viability of T98G
cells transfected with miR-221 or with scrambled sequence
treated with TMZ for 24 hrs in the presence or absence of 3 hrs
pre-treatment with ZVAD-fmk. ** p value< 0.0034 versus only
treated TMZ column, Student’s t test.
doi: 10.1371/journal.pone.0074466.g004
Hence, double-strand DNA breaks, DNA mismatch repair, and
the apoptotic pathway are activated. MGMT expression is
regulated by the methylation of its promoter. MGMT promoter
methylation lowers MGMT levels and accounts for a greater
TMZ response when associated with radiotherapy. However, a
fraction of patients with unmethylated MGMT show some TMZ
response, suggesting that promoter methylation is not the only
regulatory mechanism of MGMT expression [13,14].
In the present study, we addressed this specific issue by
investigating the involvement of miRs in MGMT regulation.
First, we characterized TMZ sensitivity in a subset of
Figure 5.  miR-221 promotes DNA damage.  (A) Alkaline
comet assay of T98G cells transfected with miR-221 and
treated with TMZ for the indicated times. (B) Analysis of γH2AX
in T98G cells transfected with scrambled control miR or
miR-221, treated with TMZ in the presence or in the absence of
MGMT cDNA, by immunocytofluorescence (upper and medium
panel) or by Western blot (lower panel). (C) Western blot
analysis of the indicated proteins upon transfection of T98G
cells with miR-221 and MGMT cDNA and TMZ treatment for 24
hrs.
doi: 10.1371/journal.pone.0074466.g005
Figure 6.  Association of miR-221 and MGMT
expression.  Mann–Whitney U test analysis was performed to
evaluate the association between miR-221 and MGMT
expression in long- and short -survival groups of patients. The
expression of miR-221 (2^-Dct) (A-B) and MGMT (2^-Dct) are
inversely correlated with patient survival (p < 0.0490 and
p = 0.043, respectively).
doi: 10.1371/journal.pone.0074466.g006
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glioblastoma cell lines and primary cells obtained from GBM
patients. We found that the analyzed glioblastoma cell lines
(T98G, LN428, U87MG, and A172) expressed different levels
of miR-221/222 and displayed a consistent difference in MGMT
expression. This inverse correlation was also observed in
glioblastoma biopsies.
Bioinformatics identified a possible miR-221/222 binding site
on MGMT. This was confirmed by a luciferase assay and
overexpression experiments. The effect of miR-221/222 on
MGMT levels was direct and not related to MGMT promoter
methylation, since miR transfection did not alter the MGMT
methylation profile. Instead, we found evidence that
miR-221/222 regulated MGMT levels, leading to increased
TMZ-induced apoptosis, reduced anchorage-independent
growth, and reduced cell viability. Overexpression of MGMT
cDNA with miR-221/222 rescued the effects on TMZ sensitivity.
This result was not restricted to glioma cells, but was obtained
also in other cancer cells sensitive to TMZ, such as human
malignant melanoma.
It has been demonstrated that MGMT may be a target also of
other miRs, such as miR-181, in GBM [28]. Zhang et al.
demonstrated that miR-181d targets MGMT 3’ UTR, and
reported an inverse correlation between miR-181d and MGMT
levels in human GBM samples, in particular in those samples in
which the MGMT promoter was unmethylated [28]. However,
the modest correlation between miR-181d and MGMT
suggested that other miRs may regulate MGMT expression.
Therefore, miR-221/222 may be part of this cohort.
MGMT expression may be regulated also thought the p53
pathway. Blough et al. provided evidence that p53 regulates
MGMT expression in murine astrocytes, and presented data
suggesting that p53 contributes to the regulation of MGMT
gene expression in the human astrocytic glioma cell line SF767
[29].
In this manuscript, we demonstrate that miR-221
overexpression increases DNA damage in glioma cells. In fact,
miR-221-overexpressing glioma cells exhibited an increase in
DNA damage markers, such as P-ATM, P-p53, cleaved PARP,
and γH2AX. These markers were activated even in the
absence of TMZ, and became increased upon TMZ treatment.
MGMT participates in the repair of DNA. Thus, miR-221/222
induces chronic MGMT downregulation, rendering the cells
unable to repair DNA damage. It is well established that
miR221/222 are oncogenic microRNAs that are upregulated in
a number of human tumors [30,31,32]. In GMB tissue and cell
lines, upregulated miR-222 and miR-221 expression correlated
with the stage of the disease, cell motility, and TRAIL response
[19,23,31,33]. We found that miR-221 is a negative prognostic
factor, since it is up regulated in short-survival patients and is
downregulated in long-survival ones. However, we did not
observe the expected correlation between miR-221 expression
and response to temozolomide/survival. Arguably, overall
survival and therapy response have to be linked to other
factors. It therefore seems that the pro-oncogenic effect of
miR-221 is more powerful than its potentiation of the response
to temozolomide.
The role of MGMT in DNA damage repair has been
investigated also in animal models. Reduced expression of this
repair enzyme has been thought to result in a spontaneous
‘mutator’ phenotype and to promote neoplastic lesions in the
presence of either endogenous or exogenous sources of
alkylation stress. Sakumi, et al. showed that Mgmt−/− mice
develop thymic lymphomas and lung adenomas to a greater
extent when exposed to methylnitrosourea (MNU), suggesting
that the DNA repair methyltransferase protected these mice
from MNU-induced tumorigenesis [34]. Sandercock et al.
reported that MGMT-deficient cells exhibited an increased
mutational burden, but only following exposure to specific
environmental mutagens [35]. Takagi et al. demonstrated that
mice with mutations in Mgmt as well as in the DNA mismatch
repair gene Mlh1 developed numerous tumors after being
administered MNU. When exposed to a sub-lethal dose of
MNU (1mM), the mutation frequency in Mgmt−/−/Mlh1−/− cells
was up to 12 times that of untreated cells; this effect was not
present in control mice [36]. Walter et al. generated transgenic
mice overexpressing MGMT in brain and liver, or in lung [37].
They found that expression of the transgene correlated with a
reduced prevalence of MNU-induced tumors in liver and in lung
and also with reduced spontaneous hepatocellular carcinoma.
Reese et al. found that overexpression of MGMT decreased
the incidence and increased the latency of thymic lymphoma
induction in mice with both heterozygous and wild type p53
alleles [38]. This protective effect was described also by Allay
et al., who reported that the incidence of lymphomas was much
lower in MGMT transgenic mice compared with controls [39].
Those studies thus suggest that MGMT, other than being
involved in the response to therapy, is also involved in DNA
repair. Therefore, its inactivation may produce devastating
effects on DNA integrity.
In summary, we have provided evidence of the existence of
an adjunct mechanism of MGMT regulation, besides promoter
methylation, involving miR targeting its 3’ UTR. We have also
shown that overexpression of miR-221/222 produces an
increase in sensitivity to TMZ via a reduction in the level of
MGMT. On the other hand, these miRs increase DNA damage,
conferring oncogenic features to glioma cells. This may link
miR-221/222 to poor GBM prognosis.
Supporting Information
Figure S1.  Methylation-specific PCR analyses for MGMT
methylation in glioblastoma human tumors. 33 glioblastoma
samples were used for analysis. The SW48 cell line and in vitro
methylated DNA (IVD) are shown as a positive control for
methylation, normal lymphocytes (NL) as a negative control for
methylation, and water (H2O) as a negative PCR control. U
and M indicate the presence of unmethylated or methylated
MGMT, respectively. Red colour is for methylated samples,
green for unmethylated and orange for undetermined samples.
(TIF)
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